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Abstract
Subarachnoid hemorrhage (SAH) is the leading cause of death in stroke patients who
suffer from vasospasms with incidence of 70%. SAH prevents sufficient oxygen supply to the
brain causing ischemia and death. FDA approved only nimodipine (NM) for treatment of
vasospasm associated with SAH. Nevertheless, NM has poor pharmacokinetic properties,
which limit its clinical efficacy. NM is susceptible to first-pass metabolism and has low
solubility and thereby poor bioavailability. The objective of this study is to assess the nosebrain pathway in brain targeting of NM-loaded lipid nanocapsules (LNCs) after intranasal
administration. Solvent-free phase inversion temperature technique was used to prepare NMloaded LNCs. Design Expert 7 was used to establish D-optimal mixture design. The model
evaluates the impact of individual and combined effects of three independent variables, X1
(Labrafac), X2 (Solutol HS 15), and X3 (water), on responses Y1 (particle size), Y2 (Zeta
potential), Y3 (polydispersity index; PDI), Y4 (drug payload), Y5 (entrapment efficiency), Y6,
Y7, and Y8 (in vitro drug release after 6, 24, and 48 h, resp.), and Y9 (solubilization capacity).
NM-loaded LNC was optimized to increase the NM payload, decrease particle size, and fulfil
suitable zeta potential, PDI, and in vitro drug release. The optimized NM-loaded LNC
revealed narrow size distribution of PDI of 0.146 ± 0.045, small particle size of 35.94 ± 0.14
nm, 5 mg/mL drug payload, spherical morphology, and appropriate drug release profile
initially and over a 3-month period. The in vivo pharmacokinetic assessment of optimized
NM-loaded LNC revealed absolute bioavailability of NM in brain (99.5%) and plasma
(102.6%) in Wistar rats after intranasal administration of NM-loaded LNCs with reference to
the IV administered NM solution. Finally, intranasal administration of NM-loaded LNCs
supported safe and effective practice to deliver NM via intranasal route to the brain via
systemic pathway attributed with NM BBB enhancement.
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1. Introduction
1.1. Drug Delivery and Nanotechnology
Throughout the last 15 years, the costs for developing new drug entities have been
increasing and the number of newly approved drug molecules decreased [1].
According to recent statistics released by the US Food and Drug Administration (FDA), the
number of approvals for new molecular entities (NMEs) and biologics license applications
(BLAs) has been fluctuating since 1993. Figure 1 demonstrates the fluctuating trend for new
drug approvals [2, 3].

Figure 1. Novel approvals since 1993 reprinted from [3].

Drug development can be divided into a drug discovery phase, a preclinical
development phase, and a clinical development phase. Drug discovery is the initial phase by
which a hit is identified, developed, and optimized to form what is called a lead structure. In
the preclinical development phase, in vitro tests as well as experiments are performed, which
fulfil regulatory and technical requirements for applying experiments on human candidates.
In the clinical development phase, the establishment of a “Development Master Plan” is
taking place. All operational procedures are documented and listed in the “Development
Master Plan” with costs, time, and goals. The number of experiments may exceed 1000 single
operations, each with enormous possible risks of failure that may end the process of drug
development.
Figure 2 illustrates the process of drug development, the time needed to accomplish
that process, and the overall probability of success at each stage [1].
13

Figure 2. Chronological sequence and success rate of the individual phases of drug development
reprinted from [1].

The upper mentioned information directs the process of drug development and
pharmaceutical industry towards diseases with huge base of population in order to be able to
retrieve large profits that cover their costs. Figure 3 correlates the contribution of therapeutic
areas and drug approvals [3].

Figure 3. Drug approvals by therapeutic area in 2016 reprinted from [3].
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Figure 3 reveals that drug approvals in the fields of gastroenterology, psychiatry, and
pulmonary, among others, have weak contributions in the total drug approvals, whereas
oncology and infectious disease drugs have strong contributions to the total drug approvals.
Therefore, there is a gap between discovering NMEs and certain therapeutic areas. The
challenges facing the process of drug development are high development costs, time, poor
pharmacokinetic and pharmacodynamics properties of the NMEs, and risk of developing
adverse drug reactions in certain population after drug release in the market leading to its
withdrawal [4].
Nanotechnology is the science of material fabrication at the nanoscale where at least
one dimension is between 1 and 100 nm. Size reduction of active pharmaceutical ingredient
and/or drug loading on nanocarriers provides a tool to target the drug to a specific site of
action or in certain tissues via passive or active targeting, enhance the delivery of poorly
water-soluble drugs [5], facilitate intracellular delivery of large macromolecules [6], enhance
the passage of drugs through tight epithelial and endothelial barriers by transcytosis
mechanism [7], enhance codelivery of more than one drug at a site of action to achieve a
combination therapy [8], combine imaging modalities besides the therapeutic agents to
visualize and reach specific site of action. [9].
Lipid vesicles were firstly described in 1960s, known as liposomes [10].
Consequently, drug delivery systems were made from organic and inorganic biomaterials. In
1976, the first system for delivery of macromolecules by using controlled release polymers
was described [11]. In addition, complicated drug delivery systems providing the ability to
control the drug release in response to changes in pH were developed [12].
In 1980, Leserman et al. introduced the first example of specific targeting of cells via
fluorescent liposomes covalently coupled with monoclonal antibody and proteins [13]. Also,
Heath et al. described specific active targeting of liposomes using antibody fragments [14]. In
1987, the concept of “stealth liposomes” was described as the first long circulating
liposomes. In the same year, Allen et al. succeeded in increasing the circulation time of
liposomes through decorating their surface by polyethylene glycol (PEG) [15].
In 1995, the first nanopharmaceutical product Doxil (doxorubicin liposome) was
approved for the treatment of AIDS-associated Kaposi’s sarcoma [16]. Figure 4 describes the
timeline for evolution of nanotechnology based drug delivery systems [17].
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Figure 4. Timeline of nanotechnology based drug delivery systems reprinted from [17].

1.2. Acute Subarachnoid Hemorrhage
Stroke or cerebrovascular disease is considered the second lethal disease throughout the globe
after cardiovascular disease. Subarachnoid hemorrhage (SAH) contributes 1-7% of strokes
[18].
1.2.1. Causes of SAH

Ruptured cerebral aneurysm as a result of trauma is the main reason for SAH in 85%
of the cases [19]. The wall of the arteries in the brain in an area called circle of Willis and
near arterial branching weakens and enlarges. The less common large aneurysms are more
likely to rupture. On the other hand, bleeding from small aneurysm is the main cause of SAH.
Figure 5 demonstrates the common sites of aneurysms [20].
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Figure 5. The most common sites of aneurysm (circles) reprinted from [20].

Nonaneurysmal perimesencephalic hemorrhage constitutes only 10% of SAH causes.
In this type of hemorrhage, the blood is located in the subarachnoid spaces around the
midbrain.

There is uncertainty regarding the origin of blood in nonaneurysmal

perimesencephalic hemorrhage. Figure 6(A) demonstrates perimesencephalic hemorrhage
revealing accumulation of blood around and in front of the midbrain. In addition, Figure 6(B)
shows a CT scan of the brain that will exclude hemorrhage from basilar arteries (rule out
normal aneurysmal hemorrhage) [19].
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Figure 6. Nonaneurysmal perimesencephalic hemorrhage reprinted from [19].

Various rare causes for SAH constitute 5%, such as tumors, drugs, sickle cell disease,
noninflammatory lesions of intracerebral vessels, inflammatory lesions of cerebral arteries,
and vascular lesions in the spinal cord [21], [22], [23].

1.2.2. Epidemiology

The incidence of SAH is 6-7 per 100000 person-years in most of the population. In
Japan and Finland the incidence of SAH is around 20 per 100000 [24]. Young patients below
55 years of age contribute to 50% of SAH patients. The probability of SAH induction
increases by age [25]. According to population based studies, it was found that the fatality
rate is 25-50% of SAH cases. Moreover, the probability of permanent disability is 50% [26].
Disability is mainly the result of vasospasm that is accompanied with SAH. Vasospasm
occurs in 38.7% after day 3 and 46% after day 9 and finally reaches up to 70% of SAH
patients [27] .

1.2.3. Treatment

Treatment of SAH is mainly based on removing hematoma (localized collection of
blood) at the bleeding site, followed by obliterating the bleeding source to prevent rebleeding, treating the vasospasm accompanied by SAH to prevent brain ischemia and death,
and finally preventing and treating SAH complications [20].

1.2.3.1. Re-Bleeding Prevention

If large hematomas are accompanied with focal neurological disorders and loss of
18

consciousness, withdrawal of blood collections should be done surgically from the bleeding
site [20]. In addition, precautions must be taken to prevent re-bleeding. If cerebral aneurysm
is present, clipping and coiling medical interventions must take place to reduce the risk of rebleeding [28], [29]. Clipping process requires opening of the skull (craniotomy) in order to
locate the aneurysm where the neck of aneurism is surrounded and supported by clips [27].
On the other hand, coiling process is performed via catheter insertion in the femoral artery in
the groin till reaching the aorta and progressing to the two vertebral and carotid arteries
supplying the brain. On one occasion when the aneurysm is located, blood clot is induced to
obliterate the aneurysm via platinum coils [28].
1.2.3.2. Vasospasm Treatment
Blood clots in SAH induce the release of oxyhemoglobin and vasoactive substances
that induce the release of vasoconstrictor peptide (endothelin-1) leading to contraction of
blood vessels’ smooth muscle. Moreover, oxyhemoglobin inhibits nitric oxide production, an
endogenous vasodilator. Finally, vasoconstriction in the blood vessels of the brain will occur
[30]. The latter process is called vasospasm which prevents good supply of oxygen to the
brain leading to ischemia and death. The incidence of vasospasm is up to 70% in SAH cases
[26]. Nimodipine (NM) is the only approved drug for treatment of vasospasms of acute SAH
[31]. It has been reported that NM improves the outcomes if administered between the fourth
and the twentieth day after hemorrhage [32].

1.3. Nimodipine
NM (Figure 7) is a 1,4-dihydropyridine L-type Ca2+-channel antagonist. It has high
lipophilic character which enables its permeability via the blood brain barrier (BBB) and
causes its bioavailability in the cerebrospinal fluid (CSF) [33]. NM is mainly utilized in SAH
management as it dilates the cerebral vessels and enhances the cerebral blood flow [34]. It
has been proven that NM decreases poor outcomes following SAH [35]. NM is used for
dementia and age-related neurodegenerative disorders as it regulates the intracellular calcium
concentration that is impaired by aging [36] [37]. Moreover, it showed improved outcomes in
cerebrovascular and Alzheimer disease patients [38]. Bork et al. proved that NM has
neurogenerative and neuroprotective effects besides its role in cerebral vasodilation [39].
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Figure 7. The chemical structure of nimodipine.

1.3.1. Pharmacokinetic Properties
The clinical efficacy of NM is limited by its poor bioavailability (5-13 % in
volunteers and 3-28 % in patients with SAH) and poor aqueous solubility (3.86 µg/mL) [40]
[41]. Not only the poor solubility but also the first-pass metabolism contributes to the poor
bioavailability. 98% of NM is bound to plasma proteins leading to a very small concentration
reaching the CSF (0.3 µg/L) which corresponds to plasma concentration of 77 µg/L in SAH
patients. Demethylation and dehydrogenation are the primary stages in NM metabolism
where it is converted into inactive pyridine analogue. The half-life of elimination of NM after
oral administration ranges from 1.7 to 7.2 h while that after intravenous (IV) administration
ranges from to 0.9 to 1.5 h [42].

1.3.2. Dosage and Administration
Nimotop® was marketed by Bayern as the best oral NM formulation. Nimotop (NM)
is administrated orally in the form of ivory-colored, soft gelatin capsules for subarachnoid
hemorrhage. NM tablet and oral solution (Nymalize®) dosage formulations were also
available in the market. 60 mg dose of NM is administered every 4 h for 21 consecutive days.
The oral dose is extremely high (360 mg/day) to overcome the poor bioavailability resulting
from poor NM water solubility and extensive first-pass metabolism [43].
In addition, NM solution for infusion was utilized for acute subarachnoid hemorrhage.
Intravenous treatment should begin as early as possible after neurological deficit occurs due
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to arterial spasm as a result of subarachnoid hemorrhage. The treatment should continue for
at least 5 days up to a maximum of fourteen days. One mg of NM (about 15 µg/kg bw/h)
should be infused each hour via a central catheter for the first two hours of treatment. The
dose should be increased after two hours to 2 mg NM per hour (about 30 μg/kg bw/h), as
long as no severe decrease in blood pressure is detected.
The total duration of treatment should not exceed 21 days when Nimotop tablets and
Nimotop solution are administered successively. Nimotop® solution should not be
administered for longer than 14 days. Also, it should not be used along with Nimotop tablets.
However, FDA has warned of IV administration of NM due to severe side effects that may
lead to death [44-47].

1.4. Contribution of Nanotechnology in Resolving Drawbacks of NM
Despite the prosperous biological effects of NM, its clinical performance is restricted
due to its low water solubility (3.86 µg/mL) and poor bioavailability (5–13%) [40, 41]. Thus,
intravenous administration of NM is one of the most potent proposed routes for
bioavailability enhancement. The commercial NM solution for infusion is composed of 17%
(v/v) PEG 400, 59.3% water, and 23.7% ethanol which is required for solubilizing
appropriate dose of NM [48]. However, this regime for NM administration is associated with
many side effects when applied in the clinic. First, NM infusion requires about 10 h to deliver
to the patient the appropriate NM dose. Second, this regime requires special equipment
(infusion pumps) and further nursing care [49]. Third, it has been reported that ethanol
injections lead to local adverse effects as inflammation and pain [40, 48]. Fourth, phlebitis
and patient incompliance may occur during IV administration of NM solution. Last but not
least, NM crystallization may take place upon dilution with injection solutions, which
subjects patients to great danger [50]. Xiong et al. formulated NM nanosuspension by high
pressure homogenization to decrease local irritation and phlebitis risks that occur during
intravenous infusion of NM [48]. In this context, Song et al. formulated NM-loaded egg
phosphatidylcholine-sodium glycocholate mixed micelles to enhance NM water solubility
and clinical applicability [51]. The upper mentioned efforts proposed solutions that increase
patient compliance and decrease local adverse effects, yet safer protocol for effective NM
delivery was not proposed.
NM was used as a model drug in many publications where novel block copolymer
nanoparticles and simple nanoparticles had been reported to encapsulate NM to achieve a
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sustained release behavior [52-56].
Many attempts were conducted to enhance the oral bioavailability of NM. Chalikwar
et al. prepared NM-loaded solid lipid nanoparticles for oral administration of NM. The
bioavailability was twice that for oral NM solution. The bioavailability was enhanced as NMloaded solid lipid nanoparticles target the intestinal lymphatic transport system. However, the
brain targeting efficiency was not studied in this study [57]. In this context, Fu et al.
fabricated NM nanocrystals for oral delivery of NM. Although NM nanocrystals are
characterized by poor in vitro dissolution properties compared to those of conventional NM
solution, it achieved appropriate bioavailability. The latter was investigated to be due to intact
NM nanocrystals macropinocytosis and caveolin-mediated endocytosis by enterocytes. The
latter enabled NM to bypass first-pass metabolism [58]. On the other hand, brain targeting
efficiency was not investigated in this study. In this frame of reference, Zhang et al.
fabricated NM-loaded carbon/lipid bilayer nanocomposite with core-shell structure for oral
delivery of NM. This nanocomposite enabled sustained release of NM with 214%
enhancement in bioavailability [59]. However, this nanocarrier was attributed to 27.3%
loading efficiency. In addition, the brain targeting efficiency in this study was not
investigated. In this framework, Basalious et al. were able to fabricate NM-loaded flexible
nanotubular mixed micelles that accomplished 232% and 208% bioavailability in plasma and
brain, respectively, after oral administration [60]. Most of the attempts that had been exerted
to resolve poor pharmacokinetics of orally administered NM succeeded to enhance the
bioavailability. However, still the dosing frequency and the brain targeting efficiency of NM
were not well resolved. There is a research gap between the brain targeting efficiency and
bioavailability of NM. The proper solution to fill in the gaps of research is to achieve high
brain targeting efficiency and low NM plasma concentrations in order to reduce the systemic
side effects of NM. In addition, a drug delivery system is required to achieve sustained
release property of NM in order to reduce the dosing frequency.

1.5. Nasal to Brain Targeting
Intranasal drug delivery to the central nervous system (CNS) is an area of increasing
attention due to the possibility of evading the BBB by taking advantage of direct transport
pathways from the nose to the brain. This opens the route for proteins, small peptides, and
hydrophilic molecules treating diseases of CNS to bypass BBB reaching different brain
regions [61]. Lipophilic drugs administered intranasally will be attributed with rapid and
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efficient absorption across the nasal mucosa, reaching the systemic circulation with 100%
bioavailability which resembles drug plasma profile of intravenous administration. After
reaching the blood stream, lipophilic molecules can reach the brain diffusing through the
BBB. The extent of drug diffusion via BBB is dependent on molecule size and log P of the
drug [62]. Only small portion of lipophilic drug will reach the brain via direct nose-brain
pathways. However, nanodrug delivery systems are reported to enhance brain targeting
efficiency of lipophilic drug via direct nose-brain pathways [63, 64]. Drugs can bypass the
BBB and reach the brain via intranasal route of administration by means of the trigeminal and
olfactory nerve systems. They represent the exposed area of the CNS as they originate in the
brain and terminate in the nasal cavity. Thus a suitable drug formulation can facilitate drug
absorption from the nasal epithelium to the nerve systems and henceforward to the brain [61].

1.5.1. Olfactory Nerve

The cranial nerve responsible for the sense of smell is called the olfactory nerve
which divides to sensory nerve fibres that come out of the nasal cavity into the olfactory
region. The latter is located above the path of the air flow, high in the nasal cavity. The
olfactory nerve fibres pass via porous bony structure (cribriform plate) and assemble in the
olfactory bulb and hence the olfactory tract to the cerebral cortex [65]. Small nanoparticles
had been reported to pass to the olfactory bulb, to the caudal pole of the cerebral hemisphere,
and into the cerebellum and cerebrum [66].

1.5.2. Trigeminal Nerve

The ophthalmic, maxillary, and mandibular nerves are the major branches of the
trigeminal nerve responsible for sensation in the facial region. These major branches
assemble at the trigeminal ganglion. The maxillary and the ophthalmic nerves are the nerves
responsible for nose-brain targeting [66]. Studies reported that drug can be transported to the
caudal brain areas via trigeminal nerve [67].

1.5.3. Transport routes and mechanisms
There are three main pathways for an intranasally administered drug to reach the
brain. The first is the systemic pathway by which the drug can pass the nasal epithelium
reaching the systemic circulation passing via BBB to the brain. The second is the olfactory
pathway by which the drug can directly pass paracellular or transcellular transport via
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olfactory neurons. The third is the trigeminal pathway where drugs are transported via
trigeminal nerve [67-72]. Only lipophilic drugs can exploit systemic pathway due to their
facile diffusion across the nasal epithelium reaching the blood circulation and diffusing to
brain via BBB. Therefore, for lipophilic drugs, brain drug levels will be similar for intranasal
and parenteral administration of those drugs [61]. However, drug loaded nanoparticles can
pass epithelium membranes paracellularly or intracellularly according to their size. if the
particle size is less than 20 nm, it can pass via tight junctions and if the particle size is in the
range of 50–500 nm, it will be endocytosed and transported intracellularly by olfactory or
trigeminal neuronal cells [61].

1.5.4. NM Nanopreparations via Intranasal Route

Zhang et al. (2004) formulated NM oil in water microemulsion (composed of
cremophore RH40, ethanol, water, and labrafil) to assess the brain targeting efficiency of NM
via nose-brain pathway in rats. The brain targeting efficiency was higher compared to IV
route [63]. In this context, Zhang et al. (2006) investigated the brain targeting efficiency of
NM methoxy poly(ethylene glycol)-poly(lactic acid) nanoparticles after intranasal
application. The latter achieved better percent of brain drug direct transport compared to that
of NM nasal solution [64].
In this study, brain targeting efficiency of NM-loaded lipid nanocapsules will be
evaluated following intranasal application. In addition, the contribution of systemic and
olfactory pathways in nimodipine brain targeting will be assessed. Solid lipid nanocapsules
are a novel drug cargo carrier that has not yet been investigated for nose-brain targeting.

1.6. Lipid Nanocapsules
Lipid nanocapsules (LNCs) are core/shell nanocargo carriers. The core is composed
of oil in which the drug in question is dissolved and a shell of tension-active rigid membrane.
LNCs are suspended in saline solution and prepared by solvent-free phase inversion
technique with size ranging from 20 to 100 nm. LNCs are attributed to monomodal size
distribution with polydispersity index (PDI) < 0.3. Moreover, the shell of LNCs is composed
of PEG dipoles and phospholipid molecules that decorate the capsule surface with negative
zeta potential. LNCs are composed of FDA constituents comprising of water, NaCl, Lipoïd®
S75-3 (soybean lecithin at 69% of phosphatidylcholine), Labrafac® WR 1349 (a triglycerides
mixture of capric and caprylic acids), and Solutol® HS 15 (mixture of free polyethylene
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glycol 660 and polyethylene glycol 660 hydroxystearate).
Solutol Hs15, water, and oil are the key parameters in controlling the particle size of
LNCs. However, the NaCl concentration plays a major role in controlling the temperature
ranges where phase inversion process takes place (phase inversion zone). Therefore, the NaCl
concentration is kept at 1.75% (w/w). Varying the amount of lipoid up to 5% does not play a
role in controlling the particle size so it was also kept constant at 1.5% (w/w). Thus, the
amounts of oil, Solutol, and water are the key parameters for controlling the particle size and
thereby affecting other key parameters like drug release profile, loading efficiency, and zeta
potential. Yet, the amounts of Solutol, water, and oil should be within certain constraints in
the feasibility domain for particle formation to take place as in the ternary diagram proposed
by Hertault et al. in 2003 [73]. The feasibility domain (the area in which desired LNCs are
formed) is defined by the following limits: water: 35-80%, oil: 10-25%, and Solutol: 10-40%.
Last but not least, LNCs are characterized by high capacity of encapsulation of
lipophilic drugs and their easy, safe, and reproducible solvent-free preparation method that
synthesizes monodispersed nanoparticles with hybrid nature between liposomes and
polymeric nanoparticles. LNCs are attributed to long-term stability reaching 18 months. In
addition, LNCs are reported to inhibit p-glycoprotein [74-76] which can be of particular
interest to our drug, as it suffers from a fast rate of brain efflux. Finally, LNCs have not been
investigated for nose-brain targeting. Thus in this study, the high potentials of LNCs will be
investigated for nose-brain targeting of NM.

1.7. Application of Statistical Experimental Design in Pharmaceutical
Product Development
Over the last few years, there was extensive research in the field of pharmaceutical
technology to develop appropriate drug delivery systems. These efforts are being exerted to
manipulate poor pharmacokinetic properties of APIs. The implementation of newly designed
drug carriers provokes vast number of experimental studies in order to evaluate the efficiency
of this carrier. Conventional experimentation is usually carried out by varying the levels of
each factor (variable) discretely at a time while keeping the rest of variables constant.
Therefore, conventional assessment of newly designed drug delivery systems and factors
affecting the formulation of successful drug delivery system requires a lot of time, human
efforts, money, and many experimental runs [77]. In addition, the traditional technique of
experimental design (one-factor-at-a-time) does not support any information about the
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position of the optima but only may reach a local optimum in the system. Moreover, the onefactor-at-a-time optimization neglects the interaction between independent variables [77, 78].
Therefore, statistical designs and mathematical models are used in the field of pharmaceutical
technology to optimize in silico newly designed drug delivery systems and reduce the waste
of resources [79]. Response surface methodology (RSM) is one of the most common
experimental design methods. D-Optimal design is one of the RSM models, which reveals the
effects of independent variables and their interaction on the response (dependent variable). In
D-optimal design, the responses in question are expressed in a model as continuous function
of the composition of the independent variables’ mixture. Thus, regions of desirable
formulation compositions satisfying the criteria imposed by the experimenter can be revealed
mathematically or graphically by the model.
In this study, the individual and combined effects of ternary blends, X1 (Labrafac), X2
(Solutol HS 15), and X3 (water), were investigated using three-factor D-optimal design on
responses Y1 (particle size), Y2 (Zeta potential), Y3 (polydispersity index PDI), Y4 (drug
payload), Y5 (entrapment efficiency), Y6, Y7, and Y8 (in vitro drug release after 6, 24, and 48
h, resp.), and Y9 (solubilization capacity). The concentrations of NM, NaCl, and lipoid S75
were kept constant. Mathematical modelling was utilized to optimize NM-loaded LNCs for
brain targeting of NM via intranasal route.
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2. Materials and Methods
2.1 Materials
2.1.1 Chemicals

Chemical

Company

Acetonitrile HPLC grade

Scharlau, Germany

Methanol HPLC grade

Scharlau, Germany

Ethanol absolute HPLC grade

Scharlau, Germany

tert-Butyl ethyl ether

Scharlau, Germany

Monobasic potassium phosphate

Scharlau, Germany

NaCl

Scharlau, Germany

Phosphoric acid

Merck, USA

Lipoid S75

Lipoid Gmbh (Ludwigshafen, Germany)

Solutol HS15

BASF, Germany

Labrafac

Gattefosse, France

Dialysis tubing cellulose membrane

Sigma Aldrich, USA

Injection saline 0.9%

Al Mottahedoon Pharma, Egypt

Formic acid

Scharlau, Germany

Nimodipine

Provided from Marcyrl for Pharmaceutical
Industries
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2.1.2. Instruments
Instrument

Origin

Water purification system

ELGA MEDICA R 15 DV25 LA-621, United
Kingdom

Ceramic hotplate stirrer, UC152

Stuart, United Kingdom

Analytical balance

Shimadzu AUY 220, Japan

Eppendorf tubes

Eppendorf, Germany

Micropipette

Eppendorf, Germany

Micropipette tips

Greiner Bio-One, Germany

pH-meter

Jenway, United Kingdom

Zetasizer (Nano ZS)

Malvern, United Kingdom
JEM-2100 JEOL, Japan

Transmission electron microscope (TEM)
Vacuum filtration System

Rocker 300SS , Taiwan

Ultrasonic degasser

Elmasonic S 60 H, Germany

Dissolution apparatus

Agilant, USA

Waterbath

Memmert Waterbath WNE 45, Germany

Membrane nylon filters, 0.45 and 0.2 µm

Waters, USA

Measuring cylinders (1000 mL, 100 mL, and Schott, Germany
50 mL)
Pyrex glass bottles (1000 mL, 500 mL, and Schott, Germany
250 mL)
Bulb pipette (1 mL, 2 mL, 5 mL, 10 mL, and Eterna, Germany
25 mL)
Volumetric flasks (10 mL, 25 mL, 250 mL, Hirschmann, Germany
500 mL, and 1000 mL)
Centrifuge

Sigma 2-16p, Germany

Freezer −20°c, no frost

Samsung, Egypt

Latex medical examination gloves

Medi-pro, Malaysia

Freezer −80°c, isotemp basic

Thermo Fisher Scientific, USA

Homogenizer, IKA ® T25 digital ultra-turrax Germany
®
HPLC waters

Alliance 2695 , USA

HPLC column

Zorbax Eclipse C18, (250*4.6mm), USA

UPLC waters

ACQuity UPLC H-Class-Xevo TQD, USA

UPLC column

ACQuity UPLC HSS C18 (50 x 2.1 mm, 1.8
μm)
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2.1.3. Software


Empower 2 (HPLC)



Mass Lynx (UPLC)



Design Expert 7.0



Origin 2016



Malvern-Zetasizer-Software-v703-PSS0012-34-EN-JP



Phoenix Winnonlin software (version 6.4, Cretara)

2.2. Methods
2.2.1. D-Optimal Design
2.2.1.1. Model Generation

Design Expert 7.0 software (Stat-Ease, Inc.,) was used to build D-optimal mixture
design. D-Optimal design built a relationship between the independent variables’
concentration and the responses by space filling sampling that generates the best subset of all
possible experiments [80]. The preliminary experiments were established to investigate the
effect of three independent variables’ concentration of ternary blends; X1 (Labrafac), X2
(Solutol HS 15), and X3 (water) using three-factor D-optimal design on Y1 (particle size), Y2
(zeta potential), Y3 (polydispersity index PDI), Y4 (drug payload), and Y5 (entrapment
efficiency). In the preliminary experiments, the amount of NM (50 mg) is kept constant. The
upper and lower limit of each independent variable and the constraints placed on the response
are summarized in Table 1. The aim of the preliminary experiments was to determine the
suitability of the constraints placed on independent variable and amount of drug on the
stability of the system. The comprehensive model was generated to determine the effect of
three independent variables’ concentration of ternary blends: X1 (Labrafac), X2 (Solutol HS
15), and X3 (water) using three-factor D-optimal design on responses Y1 (particle size), Y2
(Zeta potential), Y3 (polydispersity index PDI), Y4 (loading efficiency), Y5 (entrapment
efficiency), Y6, Y7, and Y8 (in vitro drug release after 6, 24, and 48 h resp.), and Y9
(solubilization capacity). The range of each factor was chosen based on preliminary
experiments. The upper and lower limit of each independent variable and the constraints
placed on responses are summarized in Table 2. In mixture design, the three variables are
varied at a time to add up to a total of 5 grams. Sixteen candidate points of the model were
generated (including five replicates). These points were overall centroid, vertices, axial check
blends, centers of edges, and interior blends to cover different regions of the feasibility
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domain. Characterization of the dependent variables was performed and the data are fed into
the D-optimal design model. The software derives an equation to correlate the independent
variables concentration to the responses. The D-optimal design also enables studying the
interaction between the independent variables affecting the responses. Therefore, the
preliminary experiments at 5 mg/mL NM-loaded LNCs and the comprehensive model at 1
mg/mL NM-loaded LNCs were generated.
Table 1. Feasibility domain of the preliminary experiments demonstrating the upper
and lower limits of independent variables.
Factor (independent variable)

Lower (%)

Upper (%)

X1: Labrafac

10

25

X2: Solutol HS 15

10

25

X3: water

50

80

Table 2. Feasibility domain of comprehensive model demonstrating the upper and lower
limits of independent variables and constrains placed on responses.
Factor (independent variable)

Lower (%)

Upper (%)

X1: Labrafac

10

25

X2: Solutol HS 15

10

40

X3: water

35

80

Response (dependent variable)

Constraints

Y1: particle size

Minimize

Y3: PDI

< 0.356

Y6: in vitro drug release after 6 h

15-25%

Y7: in vitro drug release after 24 h

30-50%

Y8: in vitro drug release after 48 h

50-75%

Y9: solubilization capacity

Maximize

2.2.1.2. Model Analysis
When responses fluctuate over several orders of magnitude, transformation is done.
Box-Cox plot was also used to ensure that the chosen transformation was the appropriate
choice. Fitting the response to different mathematical functions, linear, cubic, special cubic,
and quadratic polynomials were fitted to the response. Aliased functions are excluded and the
rest of the functions were compared based on the model summary statistics (value of R2) and
on the lack of fit test. The software supports the choice underlining the best function.
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2.2.2. Preparation of Lipid Nanocapsules
An amount of NM (50 mg and 10 mg NM for the preliminary and comprehensive
models, resp.) was completely dissolved in Labrafac at 90°C. Ultrapure water, Solutol HS15,
Lipoid S75, and NaCl were weighed and transferred into the 25 mL beaker containing the
amount of drug dissolved in Labrafac. The amounts of Labrafac, Solutol HS15, and water
were determined according to the points supported by the design while the amounts of
sodium chloride and Lipoid S75 were kept constant at 1.75% (w/w) and 1.5% (w/w),
respectively, in all points of the design. The three variables were varied each at a time to add
up to a total of 5 grams. The mixture is kept under temperature controlled magnetic stirring
and the temperature of the mixture is raised to 90°C and then cooled back to 60°C. The
heating and cooling cycle was repeated three times. In the third cycle, when the mixture was
cooled at 60°C, 5 g of cold water (2°C) was suddenly added to the mixture and left under
magnetic stirring for 10 min [81-91].

2.2.3. Characterization
2.2.3.1. Measuring Polydispersity Index (PDI) and Particle Size

A volume of 100 µL of NM-loaded LNCs was diluted to 10 mL by ultrapure water in
order to achieve appropriate kilo counts per second around 200 Kcps. Dynamic light
scattering (DLS) was used to measure the particle size and the polydipersity index. The
measurements were done in triplicate at 25°C using Malvern Nano ZS zetasizer. The samples
were placed in disposable sizing cuvette where the light measurement position was at
4.65mm. The refractive index of the dispersant was 1.33 while that of the material was 1.59.
The measurement was carried out at dispersant viscosity (water viscosity) of 0.8872 cP.
2.2.3.2. Measuring Zeta Potential

The zeta potential was measured at 25°C using Malvern Nano ZS zetasizer. All
samples are measured in triplicate.

2.2.3.3. NM Analysis via HPLC
- Chromatographic Conditions
2.2.3.3.1. Mobile Phase Preparation

The mobile phase used for elution consisted of 10% methanol : 70% acetonitrile :
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20% of 1% v/v acetic acid. The 70% acetonitrile, 10% methanol, and 20% of 1% v/v acetic
acid were mixed and degassed in ultrasonic bath for 5 min.
2.2.3.3.2. Instrument Setup

Zorbax eclipse C18 column (5 µm, 250 mm * 4.6 mm) was utilized for
chromatographic separation at 45°C. The mobile phase was flowed at 1.5 mL/min and the
eluent is monitored by UV detector at a wavelength of 238 nm. A volume of 100 µL of
sample was injected by autosampler
2.2.3.3.3. Serial Dilutions of NM

An amount of 80 mg NM was transferred into 100 mL volumetric flask. A volume of
80 mL absolute ethanol was added to dissolve the drug by ultrasonic radiation; then the final
volume was brought to 100 mL by absolute ethanol to prepare 0.8 mg/mL NM solution S1.
A volume of 10 mL S1 was diluted to 100 mL by solvent (20% ethanol : 80% water) to
prepare 80 µg/mL NM solution S2. NM solution of concentrations 0.4, 1.6, 6.4, 8, and 9.6
µg/mL was prepared by serial dilution from S2 as shown in Table 3.
Table 3. Preparation of nimodipine serial dilutions
Concentration (µg/mL)

Volume of 80 µg/mL NM

Volume of solvent added

solution (µL)

(µL)

0.4

50

9950

1.6

200

9800

6.4

800

9200

8

1000

9000

9.6

1200

8800

The concentrations 0.4, 1.6, 6.4, 8, and 9.6 µg/mL of solutions were used to draw the
calibration curve.
2.2.3.3.4. Calibration Curve Assessment

Three replicate injections of 0.4, 1.6, 6.4, 8, and 9.6 µg/mL NM solutions were
injected successively according to the abovementioned method. The chromatographic charts
were assessed using Empower 2 software to determine the area under the curve (AUC) for
the peak corresponding to NM. The concentrations corresponding to each AUC were
recorded on Excel sheet. The data was utilized to establish a calibration curve with NM
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concentration on x-axis and AUC on y-axis.
2.2.3.3.5. Linearity

The linearity of the calibration curve is checked by drawing a best-fit line and
establishing straight-line equation together with R2 value for the line.
2.2.3.3.6. Accuracy

Serial dilutions were prepared from 1 mg/mL NM-loaded LNCs to check the accuracy
of the method and the solvent extraction efficiency. A volume of 64 µl, 80 µl, and 96 µl of 1
mg/mL NM-loaded LNCs was diluted to 10 mL by solvent (20% ethanol : 80% water) to
prepare NM recovery solutions of 6.4, 8, and 9.6 µg/mL, respectively. Each concentration
was injected three times and the mean AUC was compared to that of 8 µg/mL NM standard
solution to determine the predicted concentration. A % recovery of 98-102 is considered to be
accepted. The % recovery was calculated as follows:

2.2.3.3.7. Precision

Inraday and interday precisions were evaluated by calculating the percentage of
relative standard deviation between replicas of equivalent concentrations.
2.2.3.3.8. Limit of Quantitation and Limit of Detection

The limit of quantitation was considered the least concentration beyond which the
linearity is deteriorated (LOQ). The limit of detection was considered to be the least
concentration at which peak corresponding to NM is still detected (LOD).

2.2.3.4. Drug Payload
A volume of 100 µl of NM-loaded LNCs was diluted to 10 mL solvent (20% ethanol:
80% water). The sample was then filtered via 0.22 um nylon syringe filter and analyzed by
the validated HPLC method described in Section 2.2.3.3.

2.2.3.5. Entrapment Efficiency (EE) Measurement
The NM-loaded LNCs were filtered via 0.22 µm syringe filter to remove any NM
precipitates [84]; then 100 µl of the filtrate was diluted to 10 mL solvent (20% ethanol : 80%
water). The sample was then filtered via 0.22 um syringe filter and analyzed by the validated
HPLC method described in Section 2.2.3.3. The EE was evaluated using the following
equation [84, 89]:
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𝐸𝐸 =

NM (mg) in 1mL filterate
𝑋 100
𝑇ℎ𝑒𝑜𝑟𝑒𝑡𝑖𝑐𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑁𝑀 (𝑚𝑔) 𝑖𝑛 1𝑚𝐿 𝑓𝑜𝑟𝑚𝑢𝑙𝑎

2.2.3.6. In Vitro Drug Release
Dialysis cellulose membrane tube of 21 mm diameter and 7 cm length was used in in
vitro drug release experiments. The molecular weight cut of the dialysis membrane is 1200014000 Dalton. The cellulose membrane was kept in saline for 1 h and one end of the cellulose
tube was ligated. A volume of NM-loaded LNCs equivalent to 2 mg NM was transferred into
the cellulose membrane tubing and the free end of the tubing was wrapped with thread. The
dialysis tube containing NM-loaded LNC was then transferred into 250 mL media composed
of 50 mL absolute ethanol and 200 mL 0.05M potassium dihydrogen phosphate with final pH
7.4 and left in shaking water bath at 37°C. The role of ethanol in media is to allow sink
condition [64]. A sample (1 mL) was withdrawn at 2, 4, 6, 24, 48, 72, and 96 h and the
volume of withdrawn samples was substituted with 1 mL fresh medium. The samples were
filtered via 0.45 µm syringe filter and injected. The samples were prone to analysis as in
Section 2.2.3.3.

2.2.3.7. Solubilization capacity
An amount of 20 mg NM was transferred to 2 g of ternary blends mixture and placed
for 24 h in shaking water bath at 37°C. Sample was then filtered and 0.1 g was transferred
into 10 mL volumetric flask; 1 mL ethanol was added to dissolve NM in the sample; then
volume was brought to 10 mL by water and analyzed by the validated method of analysis
described in Section 2.2.3.3.

2.2.3.8. Stability
Three selected NM-LNCs preparations expressing different regions in the design
space were used to assess the stability of NM-loaded LNCs. The entrapment efficiency, PDI,
particle size, and zeta potential were initially determined for the three selected formulas and
monitored after 3-month storage at 4°C in amber glass bottles.
2.2.3.9. Transmission Electron Microscope (TEM)

TEM was used to determine the morphology and particle size of NM entrapped
LNCs. A volume of 100 µl of NM-loaded LNCs was diluted to 10 mL by ultrapure water.
One drop was transferred onto a copper grid and left for 30 min to allow complete dryness.
Afterwards, one drop of 1% phosphotungestic acid was added to the dried LNCs drop and left
for 30 minutes to allow the staining process. The preparation was scanned at 120 kV and
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30000 times power of magnification.

2.2.4. Formulation Optimization of NM-Loaded LNCs
Four solutions were proposed by Design Expert based on solubilization capacity, in
vitro drug release, PDI, and particle size results. The mathematical modelling and
optimization process were performed by setting the criteria for the responses as shown in
Table 2. The formulas of higher desirability were chosen and predicted to acquire higher
drug load, small particle size, stability, and appropriate drug release profile. Therefore, the
optimized NM-LNCs were prepared at 50 mg NM level to achieve a final concentration of 5
mg/mL in order to increase the applicability and compliance of NM-LNCs for intranasal
administration.
2.2.4.1. Optimized NM-loaded LNCs Characterization and Stability Study

The optimized NM-LNC was stored at 4oC in amber glass bottles. The zeta potential,
particle size, PDI, TEM, pH, and EE were determined initially and after 3 months.
2.2.4.2. Evaluation of Precipitation Resistance Efficiency (PRE) of Conventional NM
Solution and Optimized NM-LNCs
In order to evaluate the resistance of both systems upon dilution in physiological pH
7.4 (blood), conventional NM solution and optimized NM-LNCs were diluted by phosphate
buffer saline pH 7.4 (1:200, V/V). An amount of NM (100 mg) was dissolved in 40 mL
ethanol and the final volume was brought to 100 mL by 50% water : 50% PEG 400 to prepare
NM solution (1 mg/mL). The diluted systems were analyzed after filtration via 0.2 µm nylon
membrane syringe by HPLC method (2.2.3.3). The PRE was calculated as the fraction
percent between the NM amount in the filtrate and the initial amount of NM in the system
before dilution.

2.2.4.3. Validation of the Model

The model is validated by comparing the predicted and actual values of responses of
the optimized NM-loaded LNCs. The model is evaluated by calculating the percent of bias as
follows:
% 𝐵𝑖𝑎𝑠 =

𝐴𝑐𝑡𝑢𝑎𝑙 𝑣𝑎𝑙𝑢𝑒 − 𝑝𝑟𝑒𝑑𝑖𝑐𝑡𝑒𝑑 𝑣𝑎𝑙𝑢𝑒
𝑋 100%
𝐴𝑐𝑡𝑢𝑎𝑙 𝑣𝑎𝑙𝑢𝑒
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2.2.5. In Vivo Pharmacokinetic Evaluation of Optimized NM-Loaded LNCs
in Wistar Rats
2.2.5.1. Study Design

In this experiment two groups of rats (n=16) are used. The average weight of a rat was
about 0.25 kg±0.03. Group I was given NM-loaded LNCs via intranasal route, group II was
given NM solution (1 mg/mL described in Section 2.2.4.2) intravenously. All rats are
anesthetized by 1.75 g/100g intraperitoneal injection of ethyl carbamate. Free breathing of
animals was allowed through cannulation of the trachea by a PE-200 tube. In addition, all
animals were cannulated via the carotid artery for samples withdrawal. Group I is given
around 50 µl (40–60 µl) of 5 mg/mL optimized NM-loaded LNCs at each nostril by
micropipette. Correspondingly, group II is given around 0.5 mL (0.4–0.6 mL) of 1 mg/mL
NM solution via the tail vein. The dose of NM was 2 mg/kg animal weight in both groups
[64].
2.2.5.2. Sample Collection

After administration of NM in each group, blood and brain samples are collected at
the following time intervals: 5 min, 10 min, 15 min, 30 min, 60 min, 120 min, 240 min, and
480 min. At each time point, blood samples were collected via the carotid artery; then
animals were decapitated and the brain was detached from the cranial vault. The blood
samples were centrifuged for 10 min at 6000 RPM to obtain 500 µl of plasma of each sample.
The plasma and brain tissues are preserved frozen in freezer (Thermo Fisher Scientific, USA)
at −80 degrees Celsius in anticipation of UPLC analysis.
2.2.5.3. Data Analysis

Phoenix Winnonlin 6.4 software was used to carry out noncompartmental
pharmacokinetic analysis. All results were weight- and dose-normalized. The results of
intravenous and intranasal administration were demonstrated as drug concentration-time
curves in brain tissues and plasma. Cmax and Tmax for intranasal and IV administration were
deduced directly from the concentration-time profile. The area under the curve AUC0–480
was determined by calculating the area under concentration-time profile using the linear
trapezoidal rule. The pharmacokinetic results of intranasal and IV administration was
compared and analyzed for statistical significance by one-way analysis of variance
(ANOVA) implemented by Phoenix Winnonlin 6.4 software.
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2.2.6. NM Analysis via UPLC-MS/MS
2.2.6.1. Mobile Phase Preparation

The mobile phase used for elution was composed of 85% acetonitrile : 15% of 0.1%
v/v formic acid.
2.2.6.2. Instrument Setup

The mobile phase used for elution was composed of 85% acetonitrile : 15% of 0.1%
v/v formic acid. A sample (2 µl) was injected by autosampler. ACQuity UPLC HSS C18 (50
x 2.1 mm, 1.8 μm) was utilized for chromatographic separation at 35°C. The mobile phase
was flowed at 0.25 mL/min and the eluent was monitored by LC/MS/MS detector.
Eplerenone was used as internal standard. The following tables summarize the UPLC
instrument (Table 4) as well as LC/MS/MS parameters (Table 5 and Table 6).

Table 4. The UPLC instrument parameters.
Instrument
Column

ACQuity UPLC H-Class-Xevo TQD
ACQuity UPLC HSS C18 (50 x 2.1 mm, 1.8 μm)

Column temperature

35 C

Injection volume
Mobile phase
flow rate
Internal standard (IS)
Preparation of 0.1%
formic acid
Average retention
time

2 μL
Acetonitrile : 0.1% formic acid (pH 2.7) (85 : 15, v/v )
0.25 mL/min
Eplerenone
100 µL formic acid in 100 mL deionized water
For NM : 0.69 min, for IS (eplerenone): 0.52 min

Table 5. The LC/MS/MS parameters.

Xevo TQD

Capillary

3.5 KV

Desolvation temperature

350°C

Desolvation flow

800 L/h

Cone flow

50 L/h

Source temperature

120°C
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Table 6. LC/MS/MS component parameter of NM and eplerenone.
Component/parameter

Cone volt

Collision energy

NM
Eplerenone

25

10

Fragment
(M+1)+
419.24 > 343.09
415.13 > 163.19

2.2.6.3. Preparation of Stock, Secondary, and Working Solutions

A primary standard (solution A) (100 µg/mL) was prepared by accurately weighing
and transferring amount of 10 mg NM into a 100 mL volumetric flask and diluted to volume
with methanol. A secondary standard solution B (10000 ng/mL) was prepared by accurately
transferring 10 mL from solution A, into 100 mL volumetric flask, and then diluted to
volume by methanol to obtain final concentration of 10000 ng/mL (solution B). The
secondary standard solution C (1000 ng/mL) was prepared by accurately transferring 0.5 mL
from solution A, into 50 mL volumetric flask, and then diluted to volume by methanol to
obtain final concentration of 1000 ng/mL (solution C). The tertiary standard solution D (50
ng/mL) was prepared by accurately transferring 0.5 mL from solution C, into 10 mL
volumetric flask, and then diluted to volume by methanol to obtain final concentration of 50
ng/mL (solution D).
Seven different working standard solutions of NM were prepared by accurately taking
different volumes from its secondary and tertiary solutions with appropriate dilution to 10 mL
with methanol.
Eplerenone (internal standard), 1000 ng /mL, was prepared by dissolving 10 mg
eplerenone in 100 mL methanol to give a concentration of 100 µg/mL. 1 mL from this
solution was transferred into 100 mL volumetric flask; then the volume was brought to the
mark by methanol, to give a final concentration of 1000 ng/mL.
2.2.6.4. Preparation of Calibrators
2.2.6.4.1. Preparing Calibrators for NM in Brain

Two grams of saline solution was added to blank brain. Afterwards, the
brain/saline mixture was homogenized by tissue homogenizer for 2 min at 10000 RPM. 500
mg homogenate

was taken in a dry clean test tube followed by the addition of 50 μL of

working NM standard solution dedicated for the preparation of the required spiked
concentration. Afterwards each calibration point is subjected to extraction method as will be
mentioned in Section 2.2.6.7.1. The Table 7 summarizes the preparation of NM calibrators
in brain.
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Table 7. Calibration standards in rat brain.
Brain homogenate

50 µL of working standard

Concentration of NM

(mg)

solution of NM (ng/mL)

in spiked brain (ng/g)

500

50

WS/3

5

500

100

WS/4

10

500

250

WS/5

25

500

500

WS/6

50

500

1000

WS/7

100

500

2000

WS/7

200

500

5000

WS/7

500

2.2.6.4.2. Preparing Calibrators for NM in Plasma

A volume of 975 μL blank plasma was taken in a dry clean test tube followed by
the addition of 25 μL of working NM standard solution dedicated for the preparation of the
required spiked concentration. A volume of 200 µL of the spiked samples was taken and
subjected to extraction method as will be mentioned in Section 2.2.6.7.2. Table 8
summarizes the preparation of NM calibrators in plasma.
Table 8. Calibration standards in rat plasma.
Plasma
volume
(µL)

25 µL of working
standard solution of NM
(ng/mL)

Final volume
(µL)

Concentration of
NM in spiked
plasma (ng/mL)

975

200

WS/1

1000

5

975

400

WS/2

1000

10

975

1000

WS/3

1000

25

975

2000

WS/4

1000

50

975

4000

WS/5

1000

100

975

8000

WS/6

1000

200

975

20000

WS/7

1000

500

2.2.6.5. Calibration Curve Assessment

The prepared calibration standards for NM in rat brain and plasma were injected into
UPLC-MS/MS according to the abovementioned method. The chromatographic charts were
assessed using Mass Lynx software to determine the area under the curve (AUC) for the peak
corresponding to NM. The AUC for NM is multiplied by internal standard (IS)
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concentration/internal standard area to exclude any error occurring during the extraction
process. The data was utilized to establish a calibration curve with NM concentration on xaxis and (response=AUC of NM* (IS conc./IS area)) on y-axis.

2.2.6.6. Linearity

The linearity of the calibration curve is checked by drawing a best-fit line and
establishing straight-line equation together with R2 value for the line using Mass Lynx.

2.2.6.7. Quantitative Determination of NM in Rat Brain and Plasma Samples

2.2.6.7.1. Brain Samples
A volume of 50 µL of internal standard (eplerenone 1000 ng/mL) was added to 500 g
brain sample homogenate. The samples were vortexed for 30 sec, extraction technique was
conducted by the addition of 3 mL of tert-methyl butyl ether followed by vortex for one
minute, and then samples were centrifuged (at 3000 rpm) for 5 min. A volume of 2.5 mL of
the upper organic layer was transferred accurately into another dry clean tube. The organic
layer was evaporated at 45ºC, using Eppindorf sample concentrator, till dryness (25 min/high
vapor). The residue was reconstituted in a 150 µL mobile phase, and a volume of 2 µL from
the reconstituted sample was injected into the column. The peaks were detected by ACQuity
UPLC H-Class-Xevo TQD and were interpreted in the form of reported peak areas.
Concentrations of NM in unknown samples were calculated by referring to the prepared
calibration curve.
2.2.6.7.2 Plasma Samples
A volume of 50 µL of internal standard (eplerenone 1000 ng/mL) was added to 200
µL rat plasma, and the samples were vortexed for 30 sec. Extraction technique was conducted
by the addition of 2.5 mL of tert-methyl butyl ether followed by vortex for one min; then
samples were centrifuged (at 3000 rpm) for 10 min. A volume of 2 mL of the upper organic
layer was transferred accurately into another dry clean tube. The organic layer was
evaporated at 45ºC, using Eppindorf sample concentrator till dryness (20 min/high vapor).
The residue was reconstituted in 150 µL mobile phase, and a volume of 2 µL from the
reconstituted sample was injected into the column. The peaks were detected by ACQuity
UPLC H-Class-Xevo TQD and were interpreted in the form of reported peak areas.
Concentrations of NM in unknown samples were calculated by referring to the prepared
calibration curve.
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3. Results and Discussion
3.1. Results of the Preliminary Experiments
Sixteen-run, three-factor, D-optimal preliminary experiments were utilized in this
study to investigate the appropriate constraints for formulation ingredients and correlate their
effect on the particle size, PDI, zeta potential, payload, and EE. Table 9 summarizes the
composition of each experimental run and the results of the responses.
Table 9. The results of preliminary experiments.
Run

Labrafac

Solutol

Water

Particle size (nm)

PDI

Zeta

Payload

(g)

(g)

(g)

1

0.5

0.5

4

43.29±3.83

0.184±0.009

-8.52±1.05

3.58

41.2

2

0.875

1.25

2.875

37.49±0.35

0.224±0.003

-7.24±0.02

5.19

94

3

1.25

1.25

2.5

50.5±1.76

0.141±0.001

-9.60±2.005

5.18

98.8

4

0.875

0.5

3.625

63.85±1.51

0.086±0.024

-8.00±0.195

3.93

82.2

5

0.5

0.875

3.625

29.15±0.21

0.133±0.022

-8.71±0.050

4.4

67

6

1.063

0.688

3.25

66.02±0.40

0.055±0.024

-7.96±0.765

N/A

N/A

7

0.687

0.687

3.625

44.53±1.90

0.196±0.002

-7.57±0.345

5.65

84.2

8

0.875

1.25

2.875

34.37±8.83

0.211±0.015

-6.10±0.28

5.37

102.8

9

0.5

1.25

3.25

22.97±1.03

0.118±0.012

-6.19±0.885

4.64

91.8

10

1.25

0.875

2.875

69.13±1.34

0.168±0.020

-5.32±1.9

4.52

98

11

1.25

0.5

3.25

85.29±0.71

0.056±0.015

-9.27±2.035

4.62

74

12

0.875

0.875

3.25

44.1±1.23

0.142±0.012

-7.97±1.385

4.62

86.6

13

0.5

0.5

4

42.25±6.51

0.214±0.024

-8.46±0.34

2.76

29.4

14

1.25

1.25

2.5

51.24±1.99

0.162±0.011

-6.15±0.145

4.36

85

15

0.5

1.25

3.25

24.49±0.52

0.125±0.006

-8.59±0.449

4.73

88.8

16

1.25

0.5

3.25

96.01±1.04

0.082±0.008

-11.14±2.66

5.06

78.2

potential

%

3.1.1. Fitting the Response to Different Mathematical Functions
The linear, reduced cubic, and reduced quadratic functions were the best functions for
fitting the particle size, PDI, payload, and EE, respectively, to the input values. The
independent variables concentration affects particle size, PDI, payload, and EE with
statistical significance (p value <0.05) while its effect on zeta potential showed statistical
insignificance. The lack of fit test was statistically insignificant with p values 0.7495, 0.5391,
0.1561, and 0.1808 for particle size, PDI, drug payload, and EE, respectively, where the
probability value (α) for determination of statistical significance was set at 0.05 level. The
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linear regression R2 was 0.9899, 0.9682, 0.5699, and 0.8604 for particle size, PDI, drug
loading, and EE, respectively. The adequate precision value was equal to 69.953, 14.908,
6.474, and 3.7537 for particle size, PDI, drug loading, and EE, respectively. The adequate
precision reflects the signal to noise ratio. Adequate precision higher than 4 enables the
design to navigate the whole space of experiment providing highly reliable results [92].
Table 10 summarizes the reduced regression results.
Table 10. Reduced regression results of the measured responses.

Response

Model

R2

Adjusted

Predicted

R2

R2

PRESS

Regression equation of the responses

𝐥𝐨𝐠 𝟏𝟎 𝐏𝐚𝐫𝐭𝐢𝐜𝐥𝐞 𝐬𝐢𝐳𝐞 =0.76364(Labrafac) Linear
Y1

7.428E0.9899

0.9883

0.021258(Solutol) + 0.31303(Water)

0.9847

(p<0.0001)

003

PDI= -0.062858 * water+ 47.79585 * Oil
+1.02609* Surfactant - 16.78096 * water *
Oil -0.65094* water * Surfactant - 18.68913
Reduced
Y3

cubic

* Oil * Surfactant + 4.26096 * water * Oil *
0.9682

0.9312

0.8230

7.972E-

(p=0.0001)

003

Surfactant + 1.61659* water * Oil * (waterOil)-1.83845* Oil * Surfactant * (OilSurfactant)

Reduced

Drug load =-0.20406 * water-6.12727
Y4

quadratic

0.5699

0.4526

0.2524

*

5.67

Oil+3.24053*Surfactant+2.82694 * water *
(p=0.0217)

Oil
EE =-0.89596 * water-8.57588 * Oi+4.42042

Reduced
Y5

quadratic

0.8604

0.8223

0.7339

3.97

* Surfactant+3.84226 * water * Oil

(p<0.0001)

3.1.2. Model Analysis
The internally Studentized residual plots (Figures 8, 9, 10, 11, 12, and 13) identify the
internally Studentized residuals to be normally distributed, randomly distributed through the
range of prediction, and uniformly distributed across the factors. This validates the
assumptions for the preliminary experiment and reveals adequacy of the model. Internally
Studentized residual for the preliminary experiments versus run number shows that there is
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only random scatter in the relationship between the observed particle size and order in which
the data were collected, rather than any systematic relationship. Also, Box-Cox plot for
power transforms was created to determine the model requirement for further transformation
(Figure 14). Model adequacy is shown by the power (lambda) which lied very close to the
best suggested by the test and within the test confidence intervals. In addition, the power of
responses predictability and performance of the model was demonstrated by Figure 15,
showing the outstanding correlation between the actual and predicted results for particle size
and acceptable correlation between actual and predicted results for the rest of responses.
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Figure 8. Normal probability plot of residuals validating the normality assumption for particle
size, PDI, drug payload and EE in the preliminary model.
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Figure 9. Internally Studentized residuals of the sixteen generated experiments points versus
predicted particle size, PDI, drug payload and EE of each point (preliminary model).
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Figure 10. Internally Studentized residuals for particle size, PDI, drug payload and EE versus
run number in the preliminary model.
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Figure 11. Residuals versus surfactant revealing no outliers for particle size, PDI, drug payload
and EE in the preliminary model.
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Figure 12. Residuals versus oil revealing no outliers for particle size, PDI, drug payload and EE
in the preliminary model.
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Figure 13. Residuals versus water revealing no outliers for particle size, PDI, drug payload and
EE in the preliminary model.
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Figure 14. Box-Cox plot for particle size, PDI, drug payload and EE in the preliminary model.
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Figure 15. A plot displaying the results of predicted versus actual responses for particle size,
PDI, drug payload and EE in the preliminary model.

3.1.3. Analysis of Data
Two interactive plots, contour (Figure 16) and response surface (Figure 17) plots,
were utilized to analyze the generated results. The two plots revealed that the decrease in
particle size is due to the decrease in oil and increase in surfactant percentages. Regarding
the PDI, Figures 16(b) and 17(b) demonstrated that there is an optimum region for best PDI
results. However, Figures 16(c), 16(d), 17(c), and 17(d) demonstrated that the drug load and
EE are highly affected by surfactant concentration and high oil percentage. LNC of high
Solutol and oil levels showed excellent EE. Since NM is practically water insoluble and is
completely dissolved in the oil phase (Labrafac) prior to the synthesis of LNCs, in NMloaded LNCs, NM would be either dissolved in the oil core or precipitated in the external
phase. The decrease in EE is due to physical instability of most of the preliminary trials
accompanied with NM precipitations after 1-week storage in amber glass bottles at 4°C.
Since the aim of the preliminary experiments was to scan and determine the appropriate
constraints that will suitably achieve physical stability, appropriate particle size, good PDI,
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and appropriate zeta potential for NM-loaded LNCs, the comprehensive model was prepared
to widen the constraint for Solutol to be from 10% to 40% and the amount of NM is lowered
to 10 mg instead of 50 mg to stabilize the system.

Figure 16. Contour plot showing the effect of water, oil, and surfactant on the responses of
preliminary model.

52

Figure 17. 3D response surface plot showing the effect of water, oil, and surfactant on the
responses of preliminary model.

3.2. Generation of the Comprehensive Model (1 mg/mL NM-Loaded LNCs)
The comprehensive model was generated to determine the effect of three independent
variables’ concentration of ternary blends, X1 (Labrafac), X2 (Solutol HS 15), and X3 (water),
using D-optimal design, on responses Y1 (particle size), Y2 (zeta potential), Y3
(polydispersity index PDI), Y4 (drug payload), Y5 (entrapment efficiency), Y6, Y7, and Y8 (in
vitro drug release after 6, 24, and 48 h; resp.), and Y9 (solubilization capacity). The effect of
the three independent variables’ concentration on each response will be discussed under its
specified section. Table 11 summarizes the composition of each experimental run and its
characterization results.
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Table 11. The characterization results of comprhensive model.
LNC

Labrafac

Solutol

Water

Particle size

PDI

#

%

%

%

(nm)

1*

25

39.88

35.12

34.32±0.47

0.112±0.008

2

25

10.48

64.52

111.9±2.20

3

19.25

37.12

43.64

4

10

24.69

5

10.77

6

Zeta potential

Payload

EE

Solubility

mg/mL

%

(mg/g)

-7.56±1.816

0.99

102

7.51

0.229±0.009

-8.57±0.114

0.98

96

3.99

31.5±0.32

0.204±0.009

-8.81±1.942

0.96

96

5.57

65.31

31.96±6.23

0.239±0.046

-8.11±0.603

0.95

94

4.24

40

49.23

18.84±0.22

0.124±0.034

-9.96±2.389

0.98

97

6.48

23.85

28.34

47.81

43.49±0.67

0.153±0.037

-7.88±0.261

0.95

98

5.39

7*

10.77

40

49.23

20.72±0.30

0.166±0.038

-8.20±1.569

0.98

97

6.67

8*

25

10.48

64.52

102.9±1.80

0.135±0.045

-8.91±1.036

0.96

95

4.16

9

10

10.01

79.99

56.49±1.41

0.233±0.114

-12.47±1.193

0.97

93

2.20

10

15.12

14.12

70.76

54.22±1.64

0.256±0.061

-4.57±12.71

1.01

99

3.43

11

17.65

20.56

61.79

42.3±1.37

0.164±0.051

-7.70±1.009

1.02

98

4.87

12

10

24.69

65.31

29.48±0.37

0.189±0.028

-9.35±0.951

1.01

100

3.65

13

25

39.88

35.12

37.81±1.33

0.174±0.013

-8.31±0.522

0.98

98

7.29

14

21.02

24.21

54.77

52.41±2.01

0.162±0.010

-9.01±2.851

0.98

96

5.10

15

14.27

30.2

55.53

36.7±3.87

0.356±0.051

-9.37±0.643

0.99

98

4.89

16

10

10.01

79.99

58.94±5.91

0.255±0.024

-15.67±1.701

0.94

93

2.00

3.2.1. Fitting the Particle Size, PDI, Zeta Potential, Drug Load (Payload), and EE to
Different Mathematical Functions
The linear function, reduced cubic, and special cubic were the best functions for
fitting the particle size, PDI, and zeta potential to the input values, respectively. The model is
statistically significant with p value ≤0.0001 and p=0.0135 for particle size and PDI,
respectively, while the zeta potential, drug pay load, and EE showed statistical insignificance
p=0.0729, p=0.9337, and p=0.0617, respectively. The lack of fit test was statistically
insignificant with p value of 0.0672, 0.8661, 0.1077, 0.3974, and 0.6566 for the particle size,
PDI, zeta potential, drug load, and EE, respectively, where α was set at 0.05 level. The linear
regression R2 values were 0.9640, 0.8305, 0.66, 0.015, and 0.3178 while the adequate
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precision values were equal to 38.06, 8.178, 5.389, 0.666, and 5.133 for the particle size, PDI,
zeta potential, drug load, and EE, respectively. Table 12 summarizes the analysis of variance
(ANOVA) for the particle size, PDI, zeta potential, drug load, and EE.
Table 12. ANOVA for particle size, PDI, zeta potential, drug load, and EE for the
comprehensive model
ANOVA for particle size linear model
Source

Sum of squares

DF

Mean square

F value

p value Prob > F

Model

0.649878664

2

0.324939332

173.9089519

< 0.0001

Linear mixture

0.649878664

2

0.324939332

173.9089519

< 0.0001

Residual

0.024289787

13

0.001868445

Lack of fit

0.021103795

8

0.002637974

4.139958598

0.0672

Pure error

0.003185991

5

0.000637198

Cor total

0.674168451

15
ANOVA for PDI reduced cubic model

Source

Sum of squares

Df

Mean

F value

p value

Model

0.048

7

6.92E-03

5.6

0.0135

Linear mixture

0.015

2

7.55E-03

6.11

0.0245

AB

0.031

1

0.031

25.25

0.001

AC

0.029

1

0.029

23.36

0.0013

BC

0.026

1

0.026

21.05

0.0018

ABC

0.027

1

0.027

21.7

0.0016

BC(B-C)

0.025

1

0.025

20.18

0.002

Residual

9.89E-03

8

1.24E-03

Lack of fit

1.24E-03

3

4.13E-04

0.24

0.8661

Pure error

8.65E-03

5

1.73E-03

Cor total

0.058
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ANOVA for zeta potential special cubic model

Source

Sum of squares

Df

Mean

F value

p value

Model

55.74

6

9.29

2.91

0.0729

Linear mixture

19.53

2

9.76

3.06

0.0969

AB

17.31

1

17.31

5.43

0.0448

AC

16.36

1

16.36

5.13

0.0498

BC

15.17

1

15.17

4.75

0.0572

ABC

16.88

1

16.88

5.29

0.047

Residual

28.71

9

3.19

Lack of fit

20.94

4

5.23

3.37

0.1077

Pure error

7.78

5

1.56
55

Cor total

84.45

15
ANOVA for drug load linear model

Source

Sum of squares

DF

Mean Square

F value

p value Prob > F

Model

8.24E-05

2

4.12E-05

0.069

0.9337

Linear mixture

8.24E-05

2

4.12E-05

0.069

0.9337

Residual

7.76E-03

13

5.97E-04

Lack of fit

5.26E-03

8

6.58E-04

1.32

0.3974

Pure error

2.50E-03

5

5.00E-04

Cor total

7.84E-03

15
ANOVA for EE linear model

Source

Sum of squares

DF

Mean square

F value

p value Prob > F

Model

3.13E+01

2

1.56E+01

3.48

0.0617

Linear mixture

3.13E+01

2

1.56E+01

3.48

0.0617

Residual

5.85E+01

13

4.50E+00

Lack of fit

3.20E+01

8

4.00E+00

0.75

0.6566

Pure error

2.65E+01

5

5.30E+00

Cor total

8.98E+01

15

3.2.2. Model Equation
The final equation correlating Y1: particle size as a function of concentration of
ternary blends, X1 (Labrafac), X2 (Solutol HS 15), and X3 (water) is
𝒍𝒐𝒈𝟏𝟎 𝑷𝒂𝒓𝒕𝒊𝒄𝒍𝒆 𝒔𝒊𝒛𝒆 =0.035109X1 +1.65579E-003 X2 + 0.017124 X3.
The final equation correlating Y3: PDI as a function of concentration of ternary
blends, X1 (Labrafac), X2 (Solutol HS 15), and X3 (water) is
PDI = -0.42138 X1 -0.57280 X2 -2.71678E-003 X3 +0.020873 X1 X2 +6.75696E-003 X1
X3 +0.011194 X2 X3 -2.64953E-004 X1 X2 X3 +7.00905E-005 X2 X3 (X2-X3).

3.2.3. Model Analysis
The following internally Studentized residual plots (Figures 18, 19, and 20) identify
the internally Studentized residuals to be normally distributed, randomly distributed through
the range of prediction, and uniformly distributed across the factors. This validates the
assumptions for the experiment and reveals adequacy of the model. In addition, Box-Cox plot
for power transforms was created to determine the model requirement for further
transformation (Figure 21). Model adequacy is shown by the power (lambda) which lied very
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close to the best suggested by the test and within the test confidence intervals. In addition, the
power of particle size, PDI, and zeta potential predictability and performance of the model
was demonstrated (Figure 22) by showing the appropriate correlation between the actual and
predicted results. Regarding the model predictability for drug load and EE is useless as they
are nearly the same for all experimental runs in the design space.
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Figure 18. Normal probability plot validating the normality assumption for particle size, PDI,
zeta potential, drug load, and EE (comprehensive model).
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Figure 19. Internally Studentized residuals of the sixteen generated experimental points versus
predicted particle size, PDI, and Zeta potential of each point (comprehensive model).
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Figure 20. Internally Studentized residuals versus run number for the observed particle size,
PDI, zeta potential (comprehensive model).
64

65

66

Figure 21. Box-Cox plots revealing recommended transformation for best mathematical fitting
of responses as a function of particle size, PDI, Zeta potential, drug payload and EE.
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Figure 22. A plot displaying the model's predicted particle size, PDI, and zeta potential for the
sixteen experimental designs versus the actual values in comprehensive model.
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3.2.4. Analysis of Data
Response surface (Figure 23) plot was utilized to analyze the generated results. The
plot (Figure 23 a) revealed that the decrease in particle size is observed by decrease in oil and
increase in surfactant percentage in agreement with work conducted by Heurtault et al. [73].
In 3D plot (Figure 23(a)), large particle size is denoted by red while small particle size is
denoted by blue. Most of NM-loaded LNCs with high surfactant/oil ratios are located on the
blue region and upon decreasing the surfactant/oil ratios the particle size is increased (red
zone). Small particle sizes are attributed to high surface free energy, which requires high
surfactant concentrations to stabilize those particles. The surfactant molecules have certain
solubility in oil and water; thus they are arranged at the oil-water interphase and thus
reducing the surface tension. The oil contributes to the LNCs formation by forming the core
of the LNCs. Therefore, increasing the oil concentration will increase the core volume and
increase the particle size [73, 93]. Figure 23(b) revealed that optimum PDI region with high
homogeneity of the system is exhibited by high and intermediate Solutol levels. NM-loaded
LNCs revealed monomodal and narrow particle size distribution with very good
reproducibility. Most of the PDIs are lower than 0.2. The latter ensures consistency and
reduces batch-to-batch variations. Figure (24) is demonstrating the intensity based particle
size measurements of 1mg/mL NM-loaded LNC preparations number 1, 7 and 8;
respectively.
The LNCs are characterized by negatively charged potentials due to the contribution
of the negatively charged phospholipids (lipoid) [94] and Solutol HS15 that impart negative
charge to particle due to the presence of PEG dipoles that prevent particle coalescence and
particle growth on the particle surface [91].The zeta potential is the measured charge at the
shear plane of LNC. The surface charge is very crucial factor that affects the stability of the
LNCs. The system provides NM-loaded LNC with zeta potential ranging from −4.56 to
−15.66. This negative charge increases the electrostatic repulsion forces between LNCs,
preventing their aggregation. Although the model for zeta potential is insignificant, the
interaction between the independent variables is significant with p value less than 0.05.
The drug payload and EE of NM-loaded LNCs (demonstrated in Table 11) were 0.978
± 0.022 mg/mL and 97% ± 2.4%, respectively. Drug payload and EE results of NM-loaded
LNCs (1 mg/mL) had high proximity in results without any drug precipitations upon storage
at 4°C.
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Figure 23. Response surface plot showing the effect of water, oil, and surfactant on the particle
size and PDI.
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Figure 24. Intensity based particle size and size distribution measuremnts of LNC numbers 1, 7,
and 8.
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3.3. The Effect of Drug Concentration on Particle Size of LNCs
The effect of drug concentration on the particle size was investigated. Three common
NM-loaded LNCs expressing the middle and extremes of the design space in preliminary
experiments and comprehensive models were chosen to investigate the effect of drug
concentration on particle size. Table 13 summarizes the particle size of NM-loaded LNCs at
two NM levels.

Table 13. Particle size results for three common NM-loaded LNCs at two nimodipine
levels
Ternary Labrafac
blend
%

Solutol
%

Water
%

Particle size at 50 mg
nimodipine level

Particle size at 10
mg nimodipine level

1

10

25

65

23.73±1.07nm

30.72±1.75

2

10

10

80

42.77±0.74 nm

57.70±1.75

3

25

10

65

85.29±7.58nm

107.86±6.28

The particle size of NM-loaded LNCs is dependent on drug concentration. The
particle size decreases as the amount of NM increases. The following plot demonstrated
paired t-test between 5 mg/mL and 1 mg/mL NM-loaded LNCs preparations showing a
significant reduction in size of the former with p value less than 0.05 at 0.05 α level.

Figure 25. The effect of drug incorporation on the particle size.
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This finding can be clarified in light of the study performed by Warisnoicharoen et al.
(2000) [95]. In this study, it was hypothesized that the molecular weight of oil affects its
behavior in the microemulsion formation phase inversion temperature technique. High
molecular weight oils contribute to the core formation of the microemulsion or incorporate
inside the core of microstructure. The cohesive forces among oil molecules and high surface
tension increase the particle size. In our study, NM may decrease these cohesive forces due to
its dissolution in the oil core, thereby reducing the particle size.

3.4. TEM Evaluation for Studying the Effect of NM Incorporation on
Particle Size of NM-Loaded LNC
NM-loaded LNC number 4 (R4) was chosen as a candidate for studying the
morphology of the system. The particle size of R4 is 30.7 ±1.7 nm based on laser dynamic
light scattering measurements. Figure 26 demonstrates the spherical shape of 1 mg/mL NMloaded LNC. The TEM revealed particle size of close proximity (25.53–26.68 nm) to that
retrieved from the laser dynamic light scattering measurements. The morphology plays
critical role in cellular uptake of nanoparticles. It was reported that spherical and rod shaped
nanocarriers showed superiority over other nanostructures regarding cellular uptake. In
addition spherical nanoparticles especially below 100 nm proved to achieve higher cellular
uptake compared to nanorods. In addition it had been proved that spherical nanoparticles
ranging from 30 to 50 nm are the optimal nanocarrier for cellular uptake enhancement [96].
The latter provokes NM-loaded LNCs as an appropriate candidate for brain targeting via
olfactory epithelial cells.
R4 was prepared at two NM concentrations in order to correlate the effect of drug
incorporation on the morphology of the system. R4 5 mg/mL NM-loaded LNC is donated by
R450mg, while R4 1 mg/mL NM-loaded LNC is donated by R410mg. Figures 27 and 28 are
TEM images for unstained nanoparticles of R450mg and R410mg, respectively. It was obvious
that the drug incorporation did not affect the spherical morphology of the particle. However,
it affected the oil core volume of the NM-loaded LNCs. It was found that diameter of oil core
was smaller in R450mg compared to that of R410mg. The latter may be due to role of NM in
reducing the cohesive forces between oil molecules as discussed in Section 3.3.
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Figure 26. TEM image of stained R410mg revealing spherical morphology of NM-loaded LNCs.

Figure 27. TEM image of unstained R450mg revealing the oil core of LNCs.
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Figure 28. TEM image of unstained R410mg revealing the oil core LNCs.

3.5. Method of Analysis Validation for Quantitative Determination of
Nimodipine in In Vitro Experiments
According to the method described in Section 2.2.3.3, NM was eluted at retention
time of 2.7 minutes. The following is sample of chromatographic charts of different
concentrations used in establishment of the calibration curve.
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Figure 29. Sample chromatograms of different NM concentrations.

Table 14. Peak areas of different nimodipine concentrations utilized in calibration cure
establishment.

Linearity
Conc. µg/mL

0.40

1.60

6.40

8.00

9.60

91378

380391

1492448

1825041

2342368

90558

380794

1491511

1822435

2345534

90761

381987

1491111

1819096

2340174

Avrg

90899

381057.3

1491690

1822191

2342692

SD

427.063227

829.9472

686.2382968

2980.022

2694.649

%RSD

0.4698217

0.217801

0.046004082

0.163541

0.115024

Peak areas

77

Area under the curve

2500000

2000000

1500000

y = 238117x - 12503
R² = 0.9972

1000000

500000

0
0

2

4

6

8

10

12

Concentration (µg/ml)
Figure 30. Nimodipine calibration curve.

Table 14 summarizes the area under the curve (AUC) corresponding to each NM
concentration. Calibration curve was established by plotting AUC on the y-axis and its
corresponding concentration on x-axis. The straight-line equation correlating the AUC to NM
concentration is
y = 238117x – 12503.
The fit of linear regression R² was used to judge the linearity. R2 was equal to 0.9972
indicating perfect linear relationship between AUC and NM concentration.
The repeatability results were satisfactory with a mean % SD of 1.81%. In addition,
precision results met the criteria with a mean % SD of 0.34% and 1.3% for the interday and
the intraday measurements, respectively, as shown below.
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Table 15. Precsion results for method of analysis utilized in NM in in vitro studies.

Precision AUC
Injection number

Interday

Intraday

1

1872216

1812617

2

1860369

1812399

3

1858972

1818358

4

1862442

1797465

5

1855136

1758557

Avrg

1861827

1799879

SD

6390.53628

24360.91

% RSD

0.34324007

1.353475

Precision mean

1830849.773

Precision SD

43803.70946

Precision % RSD

2.392534336

Regarding the accuracy of the method, the calculated % recovery of 6.4, 8, and 10
µg/mL test indicated that the method is accurate and suitable for quantitative determination of
NM in LNCs formulations. Table 16 summarizes the results of % recovery.
Table 16. Accuracy results for method of analysis utilized in NM in in vitro studies.

Accuracy
W.STD

6.4 µg/mL

8 µg/mL

10 µg/mL

1869514

1498864

1843190

2317217

1870365

1474272

1843070

2308980

1867167

1486522

1842906

2307885

Average

1869015.33

1486553

1843055.333

2311361

SD

1656.29174

12296.03

142.5669433

5101.199

%RSD

0.08862

0.82715

0.00774

0.22070

Assay

100.00%

79.54%

98.61%

123.67%

99.42%

98.61%

98.93%

Recovery

The limit of quantitation is set to be 0.4 µg/mL and the upper limit of quantitation is
set to be 9.6 µg/mL.
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3.6. In Vitro Drug Release
Table 17 and Figure 31 summarize % of NM in vitro release profiles for NM-loaded LNCs.
Table 17. NM in vitro release profiles.
Tim

R1

R3

R5

R6

R7

R8

R9

R10

R11

R12

R14

R15

R2

R4

R8

R13

R16

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

2

3.99

6.18

11.97

2.80

12.81

3.07

6.44

4.14

2.28

4.44

3.08

1.64

7.37

5.48

6.79

4.44

8.23

4

5.44

9.81

23.93

5.13

24.71

6.03

12.92

8.90

4.74

8.22

6.37

4.54

12.97

9.90

11.73

6.23

15.66

6

7.97

13.91

30.99

7.68

30.94

9.08

19.50

14.41

7.52

12.65

9.20

6.77

17.33

14.22

17.10

8.73

20.92

24

23.63

40.91

56.89

30.13

54.34

35.53

53.15

49.47

30.10

43.67

33.97

28.74

45.09

38.44

43.83

26.46

51.12

48

36.06

58.74

70.36

45.17

67.06

54.61

75.14

68.72

46.81

63.69

52.44

43.60

63.57

55.94

68.21

40.10

72.98

72

41.16

66.26

76.34

55.24

72.94

63.12

78.05

74.94

53.68

72.01

61.29

53.45

69.48

61.50

66.93

46.85

74.68

96

47.10

73.74

81.17

61.38

77.46

68.24

80.80

78.62

58.48

76.71

67.67

60.08

72.27

67.48

71.70

51.89

77.07

120

47.72

76.97

83.77

67.29

80.61

73.27

86.48

84.22

62.06

78.86

72.60

64.51

70.95

67.44

74.80

53.35

73.30

144

53.09

78.26

83.92

67.31

80.92

70.51

81.46

78.32

61.95

78.84

71.73

63.26

74.86

70.29

75.61

56.44

76.13
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Figure 31. Plot shows the % of nimodipine release by time.
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As shown in Figure 31, LNCs exhibited sustained release of NM in agreement with
the work conducted by Lamprecht et al., on amiodarone drug. The % of NM released reached
a plateau after 72 hours; thus in vitro drug release studies were performed for 72 h only.
Mathematical modelling and statistical analysis were run using Design Expert to determine
the effect of three independent variables’ concentration of ternary blends, X1 (Labrafac), X2
(Solutol HS 15), and X3 (water), using D-optimal design, on responses Y6, Y7, and Y8 (in
vitro drug release after 6, 24, and 48 h; resp.). These intervals are chosen to study factors that
affect drug release rate to be able to optimize the drug release rate in the optimized NMloaded LNC.
3.6.1. The Effect of Ternary Blend on Y5, Y6, and Y7
3.6.1.1. Fitting of the Model

The reduced quadratic functions were the best functions for fitting the in vitro NM
release to the independent variables concentration. The model showed statistical significance
with p values 0.001, 0.0003, and 0.0003 for in vitro NM release after 6, 24, and 48 h,
respectively. The independent variables’ interactions of Solutol-water and oil-Solutol showed
statistical significance (p<0.05). The reduced regression results for Y6, Y7, and Y8 are
summarized in Table 18. ANOVA for in vitro NM release is summarized in Table 19.
Table 18. Reduced regression results of the measured responses.

Response

Model

R2

Adjusted

Predicted

R2

R2

PRESS

Regression equation of the responses
Q 6 h=
0.57414𝑿𝟏+3.52001𝑿𝟐+0.32644𝑿𝟑

Reduced
Y6

0.8898

0.8497

0.7871

187.4

-0.089098 𝑿𝟏 𝑿𝟐-0.048402 X2 X3

quadratic

Q 24 h=
Reduced
Y7

0.71430𝑿𝟏+3.96804𝑿𝟐+0.72354𝑿𝟑
0.8320

0.7710

0.7056

508
-0.099239 𝑿𝟏 𝑿𝟐-0.053368 X2 X3

quadratic

Q 48 h=
0.80518𝑿𝟏+3.90233𝑿𝟐+0.98446𝑿𝟑

Reduced
Y8

0.8278

0.7652

0.7188

quadratic

81

639.66

-0.094915 𝑿𝟏 𝑿𝟐-0.053045X2 X3

Table 19. ANOVA for In Vitro Drug Release.
ANOVA for in vitro NM release after 6 h
Source

Sum of

df

Mean square

F value

squares

p value Prob
>F

Model

783.37

4

195.84

22.21

< 0.0001

Linear

285.51

2

142.75

16.19

0.0005

AB

450.32

1

450.32

51.06

< 0.0001

BC

355.34

1

355.34

40.29

< 0.0001

Residual

97.01

11

8.82

Lack of fit

85.49

6

14.25

6.18

0.0321

Pure error

11.52

5

2.3

Cor total

880.37

15
F value

p value Prob

mixture

ANOVA for in vitro NM release after 24 h
Source

Sum of

df

Mean square

squares

>F

Model

1436.41

4

359.1

13.62

0.0003

Linear

822.91

2

411.46

15.61

0.0006

AB

558.67

1

558.67

21.19

0.0008

BC

431.99

1

431.99

16.39

0.0019

Residual

289.95

11

26.36

Lack of fit

252.43

6

42.07

5.61

0.0391

Pure error

37.51

5

7.5

Cor total

1726.36

15
F value

p value Prob

mixture

ANOVA for in vitro NM release after 48 h
Source

Sum of

df

Mean square

squares

>F

Model

1883.49

4

470.87

13.22

0.0003

Linear

1306.91

2

653.45

18.35

0.0003

AB

511.05

1

511.05

14.35

0.003

BC

426.78

1

426.78

11.99

0.0053

Residual

391.67

11

35.61

Lack of fit

343.34

6

57.22

5.92

0.035

Pure error

48.32

5

9.66

Cor total

2275.16

15

mixture
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3.6.1.2. Model Equation

The final equations correlating Y6, Y7, and Y8 as a function of concentration of
ternary blends X1 (Labrafac), X2 (Solutol HS 15), and X3 (water) are summarized in Table 18.
3.6.1.3. Model Analysis

The following internally Studentized residual plots (Figures 32, 33, and 34) identify
the internally Studentized residuals to be normally distributed, randomly distributed through
the range of prediction, and uniformly distributed across the factors. This validates the
assumptions for the experiment and reveals adequacy of the model. In addition, Box-Cox plot
for power transforms was created to determine the model requirement for further
transformation (Figure 35). Model adequacy is shown by the power (lambda) which lied very
close to the best suggested by the test and within the test confidence intervals. In addition, the
power of predictability and performance of the model was demonstrated by Figure 36
showing the acceptable correlation between the actual and predicted results.
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Figure 32. Normal probability plot validating the normality assumption for in vitro drug
release.
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Figure 33. Plot demonstrating internally Studentized residuals versus actual values with no
outliers.
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Figure 34. Internally Studentized residuals versus run number for in vitro drug release.
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Figure 35. Box-Cox plot of in vitro NM release.
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Figure 36. Predicted % of NM release versus actual one.
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3.6.1.4. Analysis of Data

Response surface (Figures 37 a, b, c) plot was utilized to analyze the generated
results. It revealed that the increase in drug release % was achieved by decreasing the oil and
increasing the surfactant percentages.

Figure 37. 3D surface plot demonstrating the effect of ternary blend concentration on NM
release.

In vitro NM release is dependent on the particle size of NM-loaded LNCs. High
Solutol and low oil percentages lead to high NM release rate. The latter can be expressed in
the light of the effect of Solutol and oil on the particle size. NM-loaded LNCs preparations
with high Solutol and low oil percentages were attributed to high surface area to volume ratio
that increases the drug release rates. On the contrary, high oil percentage leads to larger
particle sizes of NM-loaded LNCs with smaller surface area to volume ratio and larger
particle core volume. Therefore, the diffusion distance of the drug to the medium will be
increased. In addition to that, the drug is more soluble in oil than in the release medium;
therefore partitioning of the drug into the release medium will be very slow. NM release in
most of the LNCs preparations reached a plateau after 76 hours. In addition, the drug release
is characterized by sustained release property which might be very beneficial in reducing the
frequency of NM dosing per day.
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3.7. Stability of NM-Loaded LNCs Selected from Comprehensive Model
NM-loaded LNCs numbers 1, 7, and 8 were selected for investigating the particle
size, PDI, and physical and chemical stability after 3-month storage at 4°C in amber glass
bottles and they were named LNCs “R1,” “R7,” and “R8,” respectively. R1 presents Solutol
and oil at the high level, R7 presents the high level of Solutol and low level of oil (smaller
particle size in the feasibility domain), and R8 presents the high level of oil and low level of
Solutol (larger particle size in the feasibility domain).
3.7.1. EE and Physical Stability

The three preparations were physically stable showing no NM precipitation after
storage for 3 months at 4°C in amber glass bottles. Table 20 summarizes the initial results of
drug EE and that after 3-month storage.
Table 20. Initial EE efficiency results of R1, R7, and R8 and those after 3-month storage at 40C.

Test

Initial stability %

Stability after 3M %

R1

102

103

R7

97

98

R8

95

95

The EE efficiency results for 1 mg/mL NM-loaded LNCs revealed physical stability
of the system and chemical stability of NM.
3.7.2. PDI, Zeta Potential, and Particle Size

Table 21 demonstrates the initial PDI, zeta potential, and particle size results
compared to those after 3-month storage at 4°C in amber glass bottles.
Table 21. Initial PDI, particle size, and zeta potential results compared to those after 3-month
storage of R1, R7, and R8.

Formula

Initial results

After 3M storage

PDI

Particle size

Zeta potential

PDI

Particle size

Zeta potential

R1

0.112±0.008

34.32±0.47

-7.56±1.816

0.117±0.005

36.25±0.1

-8.56±1.84

R7

0.166±0.038

20.72±0.3

-8.2±1.569

0.27±0.095

93.96±55.57

-30±6.18

R8

0.135±0.045

102.9±1.8

-8.91±1.036

0.076±0.014

105.4±0.793

-8.93±0.25
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The chosen preparations are good candidates and representable for investigating
factors that affect the stability of NM-loaded LNCs as they exemplify middle and extremes of
feasibility domain. It is obvious that R7 preparation (high level of Solutol and low level of
oil) showed poor PDI and particle size stability after 3-month storage, whereas R1 and R8
demonstrated very good stability regarding the PDI and particle size. Therefore, oil and
Solutol play a crucial role in the stability of the system.

3.8. Solubilization Capacity
Table 11 summarizes the solubilization capacity results of the system. Statistical
analysis and mathematical modelling were carried out by Design Expert to determine the
effect of ternary blend on Y9.
3.8.1. Fitting of the Model

The linear function was the best function for fitting the response to the input values.
The model is statistically significant with p value less than 0.0001. The lack of fit test was
statistically significant with p value 0.0341 at α=0.05 level. There is 3.41% chance that a
"lack of fit F value" occurs due to noise. The linear regression R2 was 0.9354 and the
adequate precision value was equal to 25.883. Table 22 summarizes the analysis of variance
(ANOVA) for linear model of the drug solubility.
Table 22. ANOVA for drug solubility.
Source

Sum of squares

DF

Mean square

F value

p value Prob > F

Model

37.47255966

2

18.73627983

94.11431

< 0.0001

Linear mixture

37.47255966

2

18.73627983

94.11431

< 0.0001

Residual

2.588040337

13

0.199080026

Lack of fit

2.337290337

8

0.292161292

5.825749

0.0341

Pure error

0.25075

5

0.05015

Cor total

40.0606

15

3.8.2. Model Equation

The final equation correlating Y9:

NM solubilization capacity as a function of

concentration of ternary blends X1 (Labrafac), X2 (Solutol HS 15), and X3 (water) is
Nimodipine Solubilization Capacity = 0.095526 𝑿𝟏 + 0.12245 𝑿𝟐 + 1.99593E-003 𝑋3.
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3.8.3. Model Analysis

The following internally Studentized residual plots (Figures 38, 39, and 40) identify
the internally Studentized residuals to be normally distributed, randomly distributed through
the range of prediction, and uniformly distributed across the factors. This validates the
assumptions for the experiment and reveals adequacy of the model. In addition, Box-Cox plot
for power transforms was created to determine the model requirement for further
transformation (Figure 41). Model adequacy is shown by the power (lambda) which lied very
close to the best suggested by the test and within the test confidence intervals. In addition, the
power of (Y9: NM solubilization capacity) predictability and performance of the model was
demonstrated by Figure 42, showing the outstanding correlation between the actual and
predicted results.

Figure 38. Normal probability plot of Studentized residuals for Y9 validating the normality
assumption.
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Figure 39. Internally Studentized residuals for Y9 versus predicted values showing no outliers.
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Figure 40. Internally Studentized residuals for Y9 versus run number.

Figure 41. Box-Cox plot revealing recommended transformation for best mathematical fitting of
Y9 as a function of independent variables.
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Figure 42. Predicted solubilization capacity values versus actual values.
3.8.4. Analysis of Data

Two interactive plots, contour (Figure 43) and response surface (Figure 44) plots,
were utilized to analyze the generated results. The two plots revealed that the increase in drug
solubility was achieved by increasing the oil and Solutol percentages. The prediction power
of the equation is very powerful as shown in Figure 45.
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Figure 43. Contour plot demonstrating the effect of ternary blend concentration on drug
solubility.

Figure 44. 3D surface plot demonstrating the effect of ternary blend concentration on drug
solubility.
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Figure 45. Predicted solubility results versus actual results.

Based on the solubility study, it is concluded that high Solutol and oil percentage will
enhance the NM-loaded LNCs drug payload. The aim of the solubility study was to
understand factors affecting the NM solubility in order to increase the drug loading in LNCs
formulation and decrease the volume of administration to be appropriate for intranasal
application and increase patient compliance.

3.9. Formulation Optimization of Nimodipine-Loaded LNCs
Optimization of NM-loaded LNCs was mathematically modelled by setting the
constraints of the responses (as shown in Table 2) in Design Expert. Four NM-loaded LNC
formulations were proposed based on solubilization capacity, in vitro drug release, PDI, and
particle size results. The proposed formulas were predicted to acquire higher drug payload,
small particle size, and appropriate drug release profile. The desirability of the formulas was
proposed by Design Expert software based on the responses ranging from 0 to 1. Figure 46
demonstrates the desirability predicted for different independent variables’ concentration of
the design space.
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Figure 46. Contour plot exhibits the optimum desirability in the design space.

The following table summarizes the solutions proposed by the software predicted to achieve
the best desirability.
Table 23. Optimum formulas proposed utilizing Design Expert and their predicted responses.

Number

OIL

Solutol

Water

Particle

Zeta

size

potential

PDI

EE

Q

Q 24

Q 48

Solubilization

6Hrs

Hrs

Hrs

capacity

Desirability

1

20.21

39.62

40.17

29.05

-7.74

0.11

98.70

15.80

36.31

50.00

6.86

0.773

2

12.64

30.64

56.71

29.23

-7.68

0.36

96.95

15.00

40.46

56.63

5.07

0.567

3

10.00

30.24

59.76

26.58

-8.42

0.36

96.62

17.28

43.92

60.33

4.78

0.539

4

18.75

12.28

68.97

72.41

-6.77

0.33

95.72

15.00

43.98

64.14

3.43

0.266

Formula number 1 was chosen because it has higher desirability, high predicted
solubilization capacity, and high amount of oil and Solutol that will govern physical, particle
size, and PDI stability. The optimized formula proposed by Design Expert enables a higher
payload of NM reaching 5 mg/mL. This high concentration may provide feasible formulation
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adopted for brain targeting of NM via the intranasal route. The D-optimum formula is
composed of 20.21% oil, 39.62% Solutol, and 40.17% water and the amount of NM is 50 mg.
The optimized NM-loaded LNC was prepared, characterized, and stored in amber glass
bottles at 4°C for monitoring its stability.

3.9.1. Characterization of D-Optimal Formulation
3.9.1.1. PDI, Zeta Potential, EE, pH, and Particle Size Measurement of Optimized NM-LNC

Table 24 summarizes the initial results of PDI, zeta potential, and particle size of the
optimized formula and those after 3-month storage.
Table 24. Initial results of PDI, Zeta potential, and particle size of the optimized NM-LNCs and
those after 3-month storage.

Initial results
Labrafac

Solutol

Water

Particle size

%

%

%

(nm)

20.21

39.62

40.17

35.94

±0.14

PDI

0.146

±0.045

Zeta potential

-23.93

±4.73

EE

pH

101%

4.5

Results after 3-month storage
Labrafac

Solutol

Water

Particle size

%

%

%

(nm)

20.21

39.62

40.17

36.16

±0.7

PDI

0.097

±0.014

Zeta potential

-14.00

±0.79

pH

99%

4.5

Figures 47 and 48 demonstrate the size distribution by intensity and zeta potential of
optimized NM-loaded LNCs, respectively.
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A

x

B

Figure 47. PDI and size distribution by intensity of optimized NM-LNCs initially (a) and after 3month storage (b).
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A

B

Figure 48. Zeta potential distribution of D-optimal formulation initially (a) and after 3-month
storage (b).
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Optimized NM-loaded LNC revealed monomodal and narrow particle size
distribution with very good reproducibility. The PDI was 0.2, which ensures consistency and
reduces batch-to-batch variations. It was characterized by negatively charged potentials. It
showed excellent particle size and PDI stability over 3-month storage period. The predicted
particle size (29.05 nm) was similar to that of the actual result (35.9 nm), indicating
appropriate prediction power of the model. The EE of optimized NM-loaded LNC was 101%
and 99% initially and after 3M storage in amber glass bottles at 4°C. The pH of D-optimal
NM-LNC was 4.5, which is appropriate for intranasal delivery while avoiding intranasal
irritation [97].

3.9.1.2. PRE

Physical stability of optimized NM-loaded LNC in phosphate buffer saline,
physiological pH of the blood, was investigated. Optimized NM-loaded LNC revealed
excellent physical stability upon dilution in phosphate buffer saline without any NM
precipitations achieving excellent PRE (101.6%). Therefore, it proved excellent applicability
for NM brain targeting via intranasal route. Oppositely, NM solution showed NM
precipitations in phosphate buffer saline with low PRE of 44.7%, increasing the incidence of
NM crystallization when injected in the blood circulation or diluted with solutions for
injection. Therefore, NM solution may lead to severe complications in patients [51].
3.9.1.3. TEM

The following TEM picture in Figures 49(a) and 49(b) demonstrates the spherical
morphology of the stained optimized NM-loaded LNC initially and after 3-month storage in
amber glass bottles at 4°C. The amount of drug did not affect the morphology. The particle
size determined from TEM is close to that determined by dynamic light scattering. TEM
images revealed stability of size and morphology of optimized NM-loaded LNC over 3month storage period.
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A

B

Figure 49. TEM of optimized NM-LNCs initially (a) and after 3-month storage (b).
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3.9.1.4. In Vitro Drug Release

The following table summarizes the in vitro drug release profile of optimized NMloaded LNC initially and after 3-month storage in amber glass bottles at 4°C.
Table 25. Initial in vitro drug release profile of D-optimal nimodipine LNC and that after 3month storage.
Time

2

4

6

24

48

72

96

Initial 1

3

14

18

46

71

85

85

Initial 2

9

16

22

57

88

96

96

Mean

6

15

20

51

79

90

90

STDEV

0.76

0.13

0.17

0.15

0.15

0.8

0.8

3M-1

11

19

27

58

77

82

82

3M-2

11

18

25

55

73

83

82

3M-3

13

19

26

60

77

82

84

Mean

12

19

26

58

75

82

83

STDEV

0.12

0.04

0.03

0.05

0.03

0.001

0.01

(hours)

Figure 50 demonstrates initial in vitro drug release profile of optimized NM-loaded

% of NM released

LNC initialy and after 3-month storage.
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Figure 50. Initial in vitro drug release profile of optimized NM-loaded LNC initially and after 3month storage.
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The homology between the initial drug release profile and that after 3-month storage
was determined by calculating the similarity factor from the following equation (Moore &
Flanner, 1996) [98]:

The similarity factor was found to be 58 (above 50) indicating that the optimized NMLNCs are characterized by stable release profile that was not deviated by time.
The model prediction for NM release profile deviated the actual results as the
mathematical modelling was carried out via Design Expert at 10 mg NM level while that in
optimized preparation was at 50 mg NM level.

3.10. In Vivo Testing
3.10.1. UPLC-MS/MS Chromatographic Results for NM Method of Analysis Utilized in In Vivo
Testing.

According to the method described in Section 2.2.6, NM was eluted at retention time
of 0.69 minutes and eplerenone (internal standard) at 0.52 minutes. The following is sample
of chromatographic charts of NM and eplerenone in plasma and brain matrices.
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Figure 51. Sample chromatogram of NM and eplerenone (internal standard) used in brain
calibrators.
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Figure 52. Sample chromatogram of nimodipine and eplerenone (internal standard) used in
plasma calibrators.

The response to each NM concentration is calculated as the ratio between AUC for
NM and that of internal standard. Calibration curves in plasma and brain matrices were
established by plotting those responses on the y-axis and their corresponding concentration on
x-axis using Mass Lynx software. The straight-line equation correlating the response to NM
concentration in plasma is
Response= 0.0158181 * x + 0.0197463.
The straight-line equation correlating the response to NM concentration in brain is
Response= 0.118424 * x + 0.675912.
The fit of linear regression R² was used to judge the linearity. R2 was equal to
0.999151 and 0.997593 for plasma and brain, respectively, indicating perfect linear
relationship between response and NM concentration in plasma and brain. The following
diagrams demonstrate the calibration curve established in plasma and brain matrices and their
residual error.
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Figure 53. Plot demonstrates the calibration curve established in plasma matrix and the
residual error.
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Figure 54. Plot demonstrates the calibration curve established in brain matrix and the residual
error.

The upper and lower limits of NM quantitation are from 1 to 1000 ng/mL in plasma
and from 0.5 to 500 ng/mL in brain tissues.
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3.10.2. In Vivo Pharmacokinetics of NM-LNCs in Wistar Rats

The results of NM plasma and brain concentrations after IV administration of NM
solution and intranasal administration of NM-loaded LNCs are summarized by Tables 26 and
27 and Figure 55. Summary of NM plasma and brain Tmax, T1/2, Cmax and AUC (0-480) is
presented by Table 28.
Table 26. Results of NM plasma concentrations after intranasal administration of optimized
NM-LNCs and IV administration of NM solution.
Nasal LNC

IV solution

Time (h)

Plasma concentration Rat1

Plasma concentration Rat2

0

0

0

0.08

31.52

35.75

0.17

31.68

20.19

0.25

105.34

68.12

0.5

193.707

98.85

1

210.68

164.14

2

186.66

144.03

4

141.49

55.9

8

80.008

44

Time (h)

Plasma concentration Rat1

Plasma concentration Rat2

0

0

0

0.08

1.5

4.8

0.17

8.45

8.46

0.25

14.9

2.44

0.5

32.5

91.24

1

521.18

635.58

2

120

145

4

53

60

8

13

20.22
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Table 27. Results of NM brain concentrations after intranasal administration of optimized NMLNCs and IV administration of NM solution.
Nasal LNC

IV solution

Time (h)

Brain concentration Rat1

Brain concentration Rat2

0

0

0

0.08

14.43

0

0.17

32.64

22.08

0.25

74.07

55.6

0.5

58.19

73.16

1

199

183.22

2

49

59.85

4

88

54.99

8

5.91

23.32

Time (h)

Brain concentration Rat1

Brain concentration Rat2

0

0

0

0.08

0

0

0.17

0

0

0.25

0

0

0.5

73.16

0

1

524

329.35

2

128

89

4

22.9

7.7

8

0

0
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Figure 55. NM brain and plasma concentration profile of intranasally administrated NM-loaded
LNCs and IV administrated NM solution.

Table 28. Plasma and Brain Tmax, T1/2, Cmax, and AUC values of NM following IV and intranasal
administration.

Route
IV solution

LNC
intranasally

Sample

Tmax
(h)

Cmax

AUC(0-480)

T1/2 (h)

Plasma

578.38±80.89
ng/mL

860.87±126.57
ng.h/mL

2.02±0.19

1
1

326.68±3.78
ng/g

509.52±46.12
ng.h/g

1.57±0.26

Brain

1

187.41±32.90
ng/mL

882.90±332.32
ng.h/mL

4.39±0.712

Plasma

1

191.11±11.16
ng/g

506.95±41.95
ng.h/g

2.96±1.73

Brain

114

h
h
h
h

After intranasal administration, NM-loaded LNCs demonstrated enhancement of NM
concentration in plasma over 8-hour period with low and constant NM plasma concentration
at each time interval. The Cmax of NM level in the plasma was 187.41 ± 32.90 ng/mL and
578.38± 80.89 ng/mL for

intranasally administered NM-LNCs and intravenously

administered NM solution, respectively (p = 0.019). The AUC0-480 for the NM plasma
concentration profile for intranasally administrated NM-loaded LNC was 882.89 ± 332
ng.h/mL. The latter is very close to that achieved from intravenously administrated NM
solution (860.87 ± 126.56 ng.h/mL). Thus, the absolute bioavailability of NM-loaded LNCs
is 102.55%. The Tmax is 1 h in both groups. The delay in Tmax of IV administered NM
solution may be justified by its poor PRE (41%). In addition, in vitro dissolution of NM
solution was performed to further investigate the delay in Tmax of IV administered NM
solution. Dissolution was done by transferring 5 mL NM solution into 500 mL phosphate
buffer saline pH 7.4 utilizing Agilent (dissolution apparatus, USA) at 37°C and 50 rpm with
paddle. It was shown (in Table 29 and Figure 56) that after 0.5 min of dissolution only 18% ±
0.4% of NM was dissolved and it reached plateau (83% ± 1.3%) after 5 min. Thus NM was
initially precipitated in dissolution medium and by time NM was redissolved.
Table 29. In vitro dissolution of NM solution.

0.5

1

2

5

10

15

20

T1

18

60

79

84

86

87

87

T2

18

58

77

82

86

86

82

Mean

18

59

78

83

86

86

84

CV%

0.4

1.4

1.3

1.3

0.3

1.6

4.1

percent released

Time
(min)

100
90
80
70
60
50
40
30
20
10
0
0

5

10

15

20

Time (min)
Figure 56. Dissolution of NM solution.
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25

In addition, particle size characterization of NM solution after reconstitution in water
(1:5; V/V low dilution) and (1:25; V/V high dilution) was performed. Particle size analysis
for NM solution was performed using dynamic light scattering to simulate the incidences that
might take place upon intravenous injection of NM solution in blood and to understand
deviations from the predicted results of pharmacokinetic properties of IV administered NM
solution. Figure 57 summarizes the results of particle size growth of NM solution upon

Particle Size (nm)

dilution.

600
458.47

500
400

318.77

300

229.17

2

385.63

388.93

403.37

234.13

236.43

222.87

242.23

10

15

20

360.30

247.33

200
100
0

Time (min)

30
60
Severe dilution of nimodipine…
low dilution of nimodipine…

Figure 57. Particle size growth of NM solution upon dilution.

Significant particle growth rate upon dilution of NM solution in small volumes of
water (1:5; V/V) might be clarified in the light of low PRE of NM solution after
reconstitution in phosphate buffer saline (41%) and the dissolution results of NM solution
which was characterized by low initial release and increased by time to 86%. Thus, NM
solution might suffer initial precipitation as shown by particle size analysis and upon high
dilution with the dissolution medium, portion of NM precipitates might redissolve or be
converted to smaller particle sizes as shown in particle size analysis after diluting NM
solution with larger volume of water (1:25; V/V high dilution). The results of these in vitro
tests might have strong correlation with those observed in in vivo study. The particle size
growth monitored at severe and low dilutions might simulate the process of NM precipitation
that might occur during the in vivo testing. NM solution was injected via rat-tail vein, which
might subject NM solution to a mixed precipitation process similar to that occurring during
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severe and low dilution of NM solution. Similar to the process that occurred in dissolution,
NM solution might precipitate in the small tail vein blood volume and as blood circulates, the
precipitates dissolve reaching the systemic circulation.
NM concentration profile in the brain showed initial absorption phase after intranasal
administration of NM-loaded LNCs. The Cmax of NM level in the brain was found to be
191.11 ± 11.158 ng/g whereas that for intravenously administered NM solution was 326.675
± 3.783 ng/g. The AUC0-480 for the NM brain concentration profile for intranasally
administrated NM-loaded LNC is 506.95 ± 41.95 ng.h/g. The latter is very close to that
achieved from intravenously administrated NM solution (509.5 ± 46.119 ng.h/g). Thus, the
absolute brain bioavailability of NM-loaded LNCs is 99.499%.
NM-loaded LNCs might reach the brain after intranasal administration via olfactory
and systemic pathways as it was reported that fluorescently labelled nanoparticles reached the
blood stream after crossing the nasal epithelium [99] and radio-labelled nanoparticles
appeared in the systemic circulation following intranasal application [100].
NM is characterized by high lipophilicity to which linear pharmacokinetic parameter
is attributed. It has been reported by Ramies in 1993 that the AUC of NM in brain
(AUCbrain)iv is directly proportional to that in plasma (AUCplasma)iv after IV administration.
Therefore, it is hypothesized that the ratio between the brain AUC portion donated via
systemic delivery after intranasal administration (Bx) and (AUCplasma)in is equal to the ratio
between (AUCbrain)iv and (AUCplasma)iv [101], where (AUCplasma)in, (AUCbrain)in, (AUCplasma)iv,
and (AUCbrain)iv, respectively, denote the AUC0-480 of NM in plasma and brain tissues
following intranasal and IV administration. Thus, two methods were implemented to
determine the contribution of the nose-brain pathway in enhancing NM brain targeting
efficiency following intranasal administration of NM-LNCs. The first model is calculating
the brain : plasma concentrations ratio (1). The second model is by calculating the “brain
drug direct transport percentage (DTP)” (2) [63].
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The DTP% exemplifies the amount of NM reaching the brain via olfactory route. In
addition, brain/plasma concentration ratios after intranasal versus IV delivery were compared
[64]. It has been found that the brain/plasma concentration ratio in intranasally administered
NM-loaded LNCs is higher than that in intravenously administered NM solution at all time
intervals except at 30 min and 120 min intervals. Figure 58 demonstrates the brain/plasma
concentration ratio of NM at each time interval. However, AUCbrain/AUCplasma ratios (drug
targeting efficiency) [63] after intranasal versus IV delivery were nearly the same. It has been
found that the drug targeting efficiency for intranasally administrated NM-loaded LNCs is
0.57 while that of IV administrated NM solution is 0.59. This indicates that olfactory
pathway plays a minor role in the uptake of NM-loaded LNCs following intranasal
administration. The latter hypothesis was supported by calculating DTP% for NM-loaded
LNCs which is found to be negligible. Intranasally administered NM-loaded LNCs revealed
excellent absolute bioavailability over 8-hour period attributed to low constant NM plasma
concentration at each time interval. The latter demonstrated that brain targeting efficiency of
NM adopted by LNCs is due to the capability of LNCs to deliver NM to brain tissues via
systemic pathway. Nevertheless, the NM plasma concentration is much lower compared to
that in intravenously administered NM solution. The latter revealed higher safety in case of
intranasal administration of NM-loaded LNC with no fatality compared to IV administration
of NM solution that was attributed to 2 animal deaths. Moreover, NM-loaded LNCs revealed
better BBB permeability rather than IV administered NM solution. The latter justifies why
the brain/plasma concentration ratio in intranasally administered NM-loaded LNCs is higher
than that in intravenously administered NM solution at all time intervals (except at 30 min
and 120 min intervals). The BBB enhancement of NM by LNC is due to the high lipophilicity
of the system and the ability of LNCs to inhibit p-glycoproteins, thereby preventing active
brain efflux of the drug [85]. In addition the NM plasma level was attributed to constant
plateau level due to slow removal of pegylated LNCs by MPS (T1/2= 4.39± 0.71 h) which
may decrease the dosing frequency.
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Figure 58. Brain/plasma concentration ratios of NM.
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4. Conclusions
Solvent-free phase inversion technique was used to prepare NM-loaded LNCs.
Mathematical modelling using Design Expert was used to optimize NM-loaded LNC. It is
characterized by narrow size distribution (PDI 0.146 ±0.045), small particle size 35.94 ± 0.14
nm, negative zeta potential, and spherical morphology revealed by TEM. Outstanding
physical and chemical stability of the optimized NM-loaded LNC were demonstrated over 3month period. Optimized NM-loaded LNCs revealed high potentials to deliver NM via
intranasal route to the brain via systemic circulation with brain absolute bioavailability of
99.5%. Low elimination NM rate and lower plasma concentration at each time interval
compared to IV administered NM solution were attributed to NM-loaded LNCs following
intranasal administration. The small innate particle size and lipophilicity of NM-loaded
LNCs enhanced the nose-blood permeability by crossing directly the nasal epithelium
reaching the blood stream. In addition the NM plasma level was attributed to constant plateau
level due to slow removal of pegylated LNCs by MPS (T1/2= 4.39± 0.71 h). Besides, the
pegylated NM-loaded LNCs might decrease the brain efflux of NM due to p-glycoprotein
inhibition. Therefore, the small innate particle size, lipophilicity, and NM brain efflux
inhibition of NM-loaded LNCs enabled higher BBB of NM compared to that following
intravenous injection of NM solution. Finally, the NM encapsulation by LNCs enabled safe
brain delivery by reducing the side effects on heart and blood pressure and increasing noseblood-brain permeability.
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